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ABSTRACT  
 
Mast cells (MCs) are best known for their critical role in allergic response but a growing body 
of evidence shows that they are important players of a variety of IgE-independent biological 
processes. It has been demonstrated that MCs are able to interact with B cells and to modulate 
both their effector and regulatory functions. Since several outcomes of the crosstalk between 
these two cell types resemble the effects of B-cell activating factor (BAFF), in this work we 
investigated the possibility that MCs could produce BAFF and we focused on its role in the 
crosstalk between MCs and B cells. The association between elevated BAFF levels and 
human autoimmunity and diseases makes the study of the role of BAFF in the B/MC 
interaction a very intriguing task.  
Through experiments of real time PCR we show that both murine and human MCs 
constitutively express BAFF mRNA. BAFF mRNA expression is associated with protein 
production both on the cell membrane and in intracellular stores, as demonstrated by flow 
cytometry and western blot experiments. Conversely, soluble BAFF was not detected, through 
ELISA, in culture supernatants of both murine and human MCs. Once demonstrated the 
production of BAFF by MCs, we were interested in elucidating its role in the B/MC crosstalk. 
Our data show that B cell survival and proliferation are reduced when using BAFF-deficient 
MCs to perform the MC/B cell co-cultures. On the contrary, BAFF produced by MCs seemed 
not to be fundamental neither in the induction of activation-induced cytidine deaminase (AID) 
expression nor in the expansion of regulatory B cells, two processes in which MCs were 
shown to play an important role. Moreover, we investigated the modulation of the expression 
of BAFF receptors on B cell surface and we have evidences that BAFF-R and TACI are 
decreased in the presence of MCs. Finally, we demonstrate that the expression of BAFF by 
MCs is particularly relevant in the context of multiple myeloma (MM). MCs are known to 
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infiltrate MM and facilitate new vessel formation. Interestingly, we show that BAFF is absent 
in the rare MCs present in bone marrow biopsies from healthy subjects while its expression, 
increases in patients with monoclonal gammopathy of undetermined significance (MGUS) 
and with MM, following the worsening of the disease. In vitro co-culture experiments with 
the myeloma cell line RPMI 8226 and the human MC line HMC-1.2 suggest that the 
malignant plasma cells are responsible of the up-regulation of BAFF on MC-surface. In 
conclusion, our data demonstrate that MCs produce BAFF and uncover an interesting relation 
between BAFF, B cells and MCs which might result particularly relevant in the context of 
clonal B cell neoplasias such as MM. 
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1. INTRODUCTION 
 
In the human body one of the principal actors that maintains the balance between “good” and 
“bad” is the immune system. A really fundamental player in human life, the immune system 
fights a daily battle against pathogens, it plays an important role in tissue homeostasis and it 
can also positively or negatively influence tumor growth. The organization is the force of the 
immune system: many types of cells are orchestrated and guided into the complexity of the 
human body. The first line of defense includes the skin and the mucosal surfaces, which 
constitute a barrier against infections. If these barriers are violated the immune system is 
readily responsive, recruiting specific cell types and leading to specific responses in defense 
to our body. The immune system is conventionally divided into two parts: the innate (non 
adaptive) and the acquired (adaptive) immune system. Classically the innate system is the part 
of the immune machinery that acts in the first line of defense, in which cells recognize and 
respond to pathogens (Parkin and Cohen, 2001). However, in recent years it has been shown 
that the role of innate immunity is much more complicated since there is a continuous 
communication with the adaptive immune system. Indeed, it is increasingly clear that innate 
and humoral immunity are not two separated compartments, but they continuously 
communicate and collaborate with each other (Litman et al., 2005). A network of different 
cell types, both of the innate and of the adaptive immune system, work together and 
orchestrate the immune response in the human body. Very important is the humoral response 
which is made by the production of antibodies (Abs) by B cells against different antigens 
(Ags). This also makes possible the existence of mechanisms of memory that lead to an 
accelerated response in the case of a subsequent contact with Ags. Also the cooperation 
between B and T lymphocytes is fundamental for a proper immune response: while B cells 
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make Abs against soluble Ags, T lymphocytes coordinate the complexity of the immune 
response. 
All immune cells originate from hematopoietic stem cells (HSC) located in the bone marrow 
and differentiate in mature cells under the influence of different cytokines. Cytokines are 
small signaling proteins that help cells of the immune system by guiding their development 
and maturation; therefore they are very important to determine the fate of several immune cell 
types. One of the most important family of cytokines is the Tumor Necrosis Factor (TNF) 
family. The most important proteins in B cell development belong to this family and one of 
these, the B-cell activating factor (BAFF), is involved both in physiological processes such as 
the development and survival of B lymphocytes, and in disease progression. 
In light of the relevancy of the communication between the innate and humoral immune 
system, the interaction between cells that compose this two parts of the immune machinery is 
gaining increasing interest. In particular, in this work I focused my attention on studying the 
role of BAFF in the crosstalk between B cells and mast cells (MCs) and its implication in 
normal and pathological contexts. 
 
1.1. MAST CELLS 
 
In 1878 Paul Ehrlich identified, for the first time, the MC in the human tissue. He defined it 
“mastzellen” (Ehrlich P, 1878; Molderings and Genetics, 2010). Ehrlich named these cells 
“mastzellen” because he speculated that their intracellular granules contained phagocytosed 
material or nutrients that could be food for neighbor cells (mast derives from the greek word 
mastos that means breast). Already at that time, Ehrlich noted that human MCs are usually 
present as round or elongated cells with a diameter ranging between 8 and 20 µm and that can 
be found in close proximity of blood vessels and nerves (Ehrlich P, 1878). MCs are 
traditionally well known for their role in allergy and in the defense against pathogens but 
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recent studies have shown that MCs play also an important role in the homeostasis of the 
immune system by interacting with different immune cell types (Gri et al., 2012). MCs are 
involved in host defense and in the support of cells homeostasis; they are important 
components of innate immunity, as well as critical effectors in acquired immunity. Therefore, 
MCs have a versatile physiological function and they should no longer be considered simply 
as “allergic cells” (Fig.1.2) (Garfield et al., 2006; Maurer et al., 2004). Physiological MC 
functions include the regulation of epithelial, smooth-muscle and endothelial cells. In 
addition, MCs affect the recruitment and activation of neutrophils, eosinophils and 
lymphocytes, and the function of nerve cells and other tissues (Maurer et al., 2003). 
 
Figure 1.1. Physiological MC functions. Physiologically, MC functions in the complex immune system include 
the regulation of epithelial cell functions (secretion and epithelial permeability), smooth-muscle cell functions 
(peristalsis and bronchoconstriction), and endothelial cell functions (blood flow, coagulation and vascular 
permeability). Moreover they affect immune functions such as the recruitment and activation of neutrophils, 
eosinophils and lymphocytes, neuronal functions such as neuroimmune interactions, peristalsis and pain, and 
other tissue functions (wound healing and fibrosis). The physiological triggers are poorly defined and might 
include growth and other tissue factors, infectious agents, neuropeptides, protein Ags and physiochemical 
conditions. (Bischoff, 2007).  
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1.1.1. Mast cell development and biology 
 
MCs originate in the bone marrow from the CD34+CD13+CD117+ multipotent HSC (MHSC) 
and then migrate to specific tissues where they complete their maturation (Fig. 1.2) (Hallgren 
and Gurish, 2011).  
 
Figure 1.2. Model of MC development. MC-development occurs in the bone marrow from a HSC that proceeds 
along the myeloid lineage through the common myeloid progenitor (CMP) and granulocyte/macrophage 
progenitor (GMP). MC progenitors (MCP) develop either from GMP or directly from HSC, circulate in the 
blood stream and finally, migrate into peripheral tissues where they mature (Moon et al., 2010). 
 
Kitamura and colleagues unequivocally established the hematopoietic origin of MCs 
(Kitamura et al., 1978, 1979a, 1979b, 1993, 2007). Unlike monocytes and neutrophils, MCs 
circulate in the peripheral blood as immature cell precursors (MCPs) and then enter in 
peripheral sites where they proliferate and differentiate into morphologically identifiable 
MCs. In mice, MCs are identified either as connective tissue (CTMC) or mucosal (MMC) 
MCs (Fig. 1.3). 
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Figure 1.3. Development of MCs from the multipotent HMC. MHSC multipotent HMC, CMP common 
lymphoid progenitor, MCP MC-commited progenitor, MMC mucosal MC, CTMC connective tissue-type MC 
(Kitamura et al., 2007). 
 
While CTMCs are found in the skin and peritoneal cavity and express the MC proteases 
MMCP-4, -5, and -6 and carboxypeptidase, MMCs are mainly present in the intestinal lamina 
propria and in the lung and are positive for MMCP-1 and -2. MMCs are expanded above all 
during T cell-dependent immune responses to parasites while CTMCs exhibit little or no T 
cell dependence (Moon et al., 2010). In the human system, MCs are classified on the basis of 
the specific serine protease which can be found in their granules: MCs that produce tryptase 
(MCt) and are predominant in the alveolar septa and in the small intestinal mucosa, MCs that 
produce chymase (MCc) and are present in the synovial tissue, and MCs that produce both 
tryptase and chymase (MCtc) and are localized in skin, tonsils and small intestinal submucosa 
(Fig. 1.4) (Irani and Schwartz, 1994; Irani et al., 1986).  
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Figure 1.4. MC populations in humans and mice. Both in mice and humans, MCs can be subcategorized into 
populations defined by their anatomical location and/or mediator content, such as proteoglycans or proteases 
(Adapted from Galli et al., 2011). 
 
An important role in the development and maturation of MCs is played by cytokines such as 
IL-3, IL-6 and IL-4 (Chen et al., 2005; Kulka and Metcalfe, 2005), but certainly one of the 
most important signals from tissues for local MCs is stem cell factor (SCF). The receptor that 
binds SCF on the MC is cKit (or CD117): this receptor is present on hematopoietic lineages 
early in differentiation, but MCs are the only terminally differentiated hematopoietic cells that 
still express c-Kit at high levels. Both in human and in mice SCF is a fundamental survival 
factor. The importance of the SCF:cKit axis in MC-development was understood thanks to the 
usage of the mouse strains W/Wv, Sl/Sld and Wsash that have SCF or c-Kit mutations; indeed 
severe defects in the production of MCs can be observed in these mice (Jarboe and Huff, 
1989). Moreover, MCs from patients with systemic mastocytosis exhibit activating mutations 
in cKit (Akin and Metcalfe, 2004; Akin et al., 2004).  
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1.1.2. Mast cell receptors, co-stimulatory molecules and soluble mediators 
 
The heterogeneity of MCs is dependent on tissue distribution and is reflected by their ability 
to react to multiple stimuli and to switch numerous Immunoglobulin (Ig) E-dependent and -
independent activation pathways (Frossi et al., 2004). MCs respond to many cytokines, 
chemokines and hormones (Galli et al., 2005a): indeed, they express on their surface a broad 
array of receptors that regulate MC-activation such as FcεRI, Fcγ, Toll like receptor (TLR), 
complements receptor, cytokine, hormone chemokine receptor (summarized in table 1.1).  
 
Table 1.1. MC membrane-bound receptors. This table shows receptors expressed on MC surface. They are 
divided into three big families: FcR, receptors for endogenous molecules and for co-stimulatory molecules. This 
variety of membrane-bound receptors can regulate MC-activation. (Gri et al., 2012). 
 
The membrane-bound receptors expressed by MCs are divided principally into three 
categories: Fc receptors (FcR), receptors for endogenous molecules and co-stimulatory 
molecules. Among the family of FcR, we find the high affinity IgE receptor, FcεRI, that leads 
to the classical MCs activation after binding of high-affinity IgE (See paragraph 1.13) (Kinet, 
1999). MCs also express TLR, that lead to an IgE-independent activation of these cells. 
Human MCs express TLR1, TLR2, TLR3m, TLR4, TLR6 and TLR9 but not CD14 or 
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functional CD48 (Marshall, 2004). MCs respond to the binding of TLR ligands by secreting 
cytokines, chemokines, and lipid mediators and some studies have found that TLR ligands 
can also cause degranulation, although this finding is contentious (Hofmann and Abraham, 
2009). In addition, stimulation via TLR can synergize with signaling via the FcεRI, 
potentially enhancing the response of the cells to Ag in vivo (Sandig and Bulfone-Paus, 2012). 
MCs also express major histocompatibility complex (MHC) class I and II molecules; in 
particular, the expression of the MHC class II receptor granted MCs the ability to process and 
present Ags directly to T cells with preferential expansion of Ag-specific regulatory T cells 
over naive T cells (Kambayashi et al., 2009). Recent observations show that MCs express 
various classes of co-stimulatory molecules that significantly modulate MC-function. These 
molecules might therefore contribute to the outcome of MC-associated pathologies and 
represent new therapeutic targets in such diseases (Bachelet and Levi-Schaffer, 2007). Among 
the co-stimulatory molecules we can find TNF family members such as CD40L, OX40L, Fas 
or TRAIL-R. In particular, CD40L was shown to play a relevant role in the context of the 
interaction between MCs and B lymphocytes. Several studies have detected CD40L on the 
surface of MCs even if the expression levels were shown to be different depending on the cell 
source and on the type of MC-activation (Gauchat et al., 1993; Merluzzi et al., 2010; 
Pawankar et al., 1997). It has been demonstrated that activated MCs can regulate CD40 
surface expression on unstimulated B cells and that the interaction between B cell-expressed 
CD40 and CD40L on MCs was involved in the B cell differentiation into CD138+ plasma 
cells and in selective IgA secretion (Merluzzi et al., 2010). Moreover, the CD40L/CD40 axis 
plays a significant role in MC-driven expansion of IL-10–competent B cells in vitro (Mion et 
al., 2014a). 
Depending on the type of stimuli that they receive, MCs secrete different products that can 
trigger varied and different immune responses (Frossi et al., 2004). MC-derived soluble 
mediators are reported in table 1.2 and they can be divided into two main categories: 
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preformed mediators, such as histamine, proteoglycans, neutral proteases and cytokines such 
as TNF-α, or newly synthesized mediators such as cytokines, chemokines, lipid mediators, 
growth and angiogenic factors (Galli et al., 2005b; Metz and Maurer, 2007).  
 
Table 1.2. Major MC-derived mediators. The table show MC soluble products. This mediators can be divided 
into two categories: preformed and newly synthesized mediators. These products are all important in the 
regulation of both innate and acquired immunity (Gri et al., 2012). 
 
The rapid release of MC mediators is important for the onset of the immune response at the 
site of action because they are able to modulate immune-cell trafficking and to provide co-
stimulatory signals for cell activation. One of the most important and abundant of these 
mediators is histamine. Histamine is a vaso-active amine that is stored in MC granules and it 
binds to specific receptors on several cell types (Caron et al., 2001). Moreover, an important 
early released MC product is TNF-α. This cytokine derives from the rapid release of 
preformed stores of the cytokine but can also be synthesized as a newly formed molecule 
(Gordon and Galli, 1990) and it plays a crucial role in innate immunity (Henz et al., 2001). 
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Other pre-synthesized molecules that protect against parasites and venoms are serine 
proteases, chymase, tryptase and metalloprotease carboxypeptidase A (Metz and Maurer, 
2007). Concerning newly synthesized products, MCs can produce arachidonic acid-derived 
prostaglandins and leukotrienes that improve the innate response by increasing MC number at 
the inflammatory site, through the recruitment of immature MCs and progenitors (Weller et 
al., 2005). The compounds secreted by MCs can also contribute to the acquired immune 
response since they are mediators of the activation and recruitment of B and T cells (Ott et al., 
2003). 
 
1.1.3. Mast cell activation 
 
It is now well accepted that MCs are true sensors of the microenvironment: these cells 
respond to a wide spectrum of immunological and non-immunological signals in a rapid and 
selective manner. For this reason, these cells are armed with a large repertoire of cell-surface 
receptors, able to interact directly or indirectly with pathogens (Rao and Brown, 2008). MC 
activation has been classically distinguished into IgE-dependent and IgE-independent 
activation. MCs present a multiplicity of G-protein-coupled receptors and other recognition 
sites on their surface which are involved in MC activation under physiological and 
pathological conditions. The best characterized mechanism of MC activation is the cross-link 
of IgE to FcεRI on the MC surface by Ag contact (Molderings and Genetics, 2010). The 
FcεRI is a constitutively expressed tetrameric receptor that comprises the IgE-binding α 
chain, the membrane-tetraspanning β chain and a disulfide-linked homodimer of the γ chains 
with high affinity for IgE (Rivera and Olivera, 2008). The interaction of a specific Ag with 
IgE already bound to FcεRI (IgE-presensitized MC) leads to the aggregation of FcεRI. 
Aggregation of FcεR1 by polyvalent Ag recognized by bound IgE activates MCs and is the 
basis for anaphylaxis and other allergic diseases. FcεR1 density on the surface of MCs is 
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upregulated in the presence of elevated free IgE levels and in the presence of IL-4, thus 
enhancing activation (Stone et al., 2010).This interaction initiates a series of biochemical 
events. The result of this events is MC-degranulation after which there is release of 
biologically active mediators with immunoregulatory or immunomodulatory effects, 
including histamine, proteases, arachidonic acid metabolites, cytokines and chemokines. 
Through the release of these molecules, MCs act a series of events that result in both 
immediate and late-phase allergic responses. (Siraganian, 2003; Metcalfe et al., 1997). This 
process is summarized in Fig. 1.5. 
 
Figure 1.5. MC activation. Cross linking of IgE on the MC by an allergen stimulates phosphorylation of 
immunoreceptor tyrosine based activation motifs (ITAM) in the signaling chains of the IgE Fc receptor, which 
then initiates multiple signaling pathways. These signaling pathways stimulate the release of MC-granule 
content (Abbas et al., 2012)). 
 
The Ag-driven aggregation of IgE-occupied FcεRI leads to the phosphorylation of 
immunoreceptor tyrosine based activation motifs (ITAMs) by Lyn kinase and the activation 
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of Syk kinase through ITAM binding. Then, Fyn kinase is also activated and this activation is 
important for phosphorylation of Gab2 that is involved in activation of Phosphatidylinositol-
4,5-bisphosphate 3-kinase (PI3K) activity. Syk and Lyn phosphorylate several adaptor 
proteins that regulate MC activation, such as Linker for activation of T cells (LAT) and Non-
T cell activation linker (NTAL). LAT regulates the activation of phospholipase Cγ (PCL-γ) 
that cleaves phosphatidylinositolo-4,5-bisphosphate in two second messengers, that are the 
inositol-1,4,5-trisphosphate (IP3) and the membrane-bound 1,2-diacylglycerol (DAG). IP3 
binds to its receptor on the membrane of the endoplasmatic reticulum and leads to an increase 
of Ca2+ in MC cytoplasm. The wave of Ca2+ is involved in activation of Ca2+-dependent 
kinases and leads to MC degranulation and to activation of NF-kB and other transcriptional 
factors necessary for the regulation of gene expression (Rivera and Gilfillan, 2006).  
Concerning the IgE-independent activation, several stimuli different from IgE/Ag are known 
to promote MC responses. Indeed, some polybasic molecules, peptides, lectins and dextran 
derivatives were shown to induce the release of histamine from MCs. (Galli et al., 1999). The 
list of IgE-independent MC agonists varies between the murine and human system and also 
among human MCs from different body sites (Bischoff, 2007). This stands particularly true in 
the case of TLR ligands, Differently from the human counterpart, murine MCs can be easily 
activated by lipopolysaccharide (LPS) since they express CD14 in addition to TLR4 
(Varadaradjalou et al., 2003). Supajatura and coworkers observed quantitative and qualitative 
differences in the activation of MCs via TLR2 and TLR4 stimulation. TLR2-mediated MC 
activation by peptidoglycan leads to degranulation and production of IL-4 and IL-5, in 
contrast to TLR4-mediated MC activation, in which TNF-α, IL-1β, IL-6, and IL-13 are the 
major cytokines produced (Supajatura et al., 2002). 
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1.1.4. Mast cells: crosstalk with other immune cells 
 
MCs may influence the development, intensity and duration of adaptive immune responses 
that contribute to host defense, allergy and autoimmunity. MCs interact with several cells 
among which dendritic cells (DCs), lymphocytes, endothelial cells and fibroblasts and other 
cells of the immune system (Fig.1.6). Concerning the crosstalk between MCs and DCs, there 
are both in vivo and in vitro evidences that MCs have the potential to influence the migration, 
maturation and function of DCs (Galli and Tsai, 2008; Galli et al., 2005a). Moreover, it has 
been demonstrated that MC products can influence the maturation of DCs at sites of 
inflammation (Mazzoni et al., 2006). 
 
Figure 1.6. MCs can interact with several cell types. The MC surface molecules and secreted products that can 
influence various aspects of the biology of DCs, ephitelial cells, neutrophils, T cells and/or B cells and others 
are presented. MC activation with IgE and specific Ag results in the secretion of a diverse range of products. 
Some of these products can also be released by particular MC populations that have been stimulated through 
TLRs or through other cell surface receptors that can interact with specific cytokines, products of complement 
activation or pathogens, endogenous peptides and so on (Abraham and St John, 2010). 
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Several reports have demonstrated MC ability to modulate T cell function, in different 
immunological contexts (Galli et al., 2005a). MCs were shown to induce Ag specific CD8+ T 
cell activation and proliferation (Orinska et al., 2005), but also to interact with regulatory T 
cells that can inhibit MC degranulation through cell-cell contact. In particular, it has been 
found that the interaction of OX40-expressing regulatory T cells with OX40L-expressing 
MCs inhibited the extent of MC degranulation in vitro and the immediate hypersensitivity 
response in vivo (Gri et al., 2008). MCs can interact with natural killer cells (NK), 
eosinophils, myeloid derived suppressor cells and neutrophils. Activated MCs can induce NK 
cell accumulation in different disease models. For instance, immune surveillance by MCs is 
important for NK cell recruitment and viral clearance during Dengue infection (St John et al., 
2011). It has been demonstrated that in murine infection peritonitis some MC-derived 
molecules have a role in the recruitment of neutrophils (Ramos et al., 1991). Although the 
interaction between MCs and neutrophils has been established, the receptor-ligand pairs that 
might physically mediate the crosstalk between these two cell populations have not yet been 
described. Finally, there are preliminary studies that disclose a novel relationship between 
MCs and myeloid suppressor cells and Treg (Yang et al., 2010b). 
 
B/MC interaction 
 
Concerning the crosstalk with cells of the adaptive immune system, the existence of an 
interplay between B cells and MCs or basophils has been disclosed by diverse evidences. 
FcRs on the surface of MCs or basophils represent the most immediate link between these 
cells (Merluzzi et al., 2014) and the engagement of FcγR by IgG has been related to different 
pathologies (Malbec and Daëron, 2007). As already mentioned, MCs produce a broad array of 
cytokine, such as IL-4, IL-5, IL-6 and IL-13, that are known to regulate, in combination with 
other factors, B cell development, survival and function. Co-stimulatory molecules are the 
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factors that support cytokine in this function, and the CD40/CD40L axis plays a particularly 
relevant role in the B/MC interaction (Pawankar et al., 1997). The crosstalk between these 
two cell types was first described by Gauchat and coworkers which demonstrated that MCs 
can interact with B cells to induce the production of IgE, in presence of IL-4 but in absence of 
T cells. They also shown  that Ab class switch recombination (CSR) could occur in peripheral 
organs such as lung or skin and that MCs could be responsible of this process  (Gauchat et al., 
1993). The contribution of MCs to  Ab class switching is not unique to the IgE, but it occurs 
also for IgA. In our laboratory, it has been demonstrated that MCs can directly induce the 
differentiation of activated B cells into IgA-secreting CD138+ plasma cells. Moreover, a 
concomitant accumulation of MCs and IgA was shown to occur within inflamed tissues in 
bioptic samples of inflammatory bowel disease patients (Merluzzi et al., 2010). This 
observation reinforces the idea that the B/MC crosstalk may contribute to T-independent IgA 
response in the intestinal lamina propria and it leads to hypothesize a link between MCs and 
plasma cells. In addition to cytokines and membrane-bound molecules, B cells and MCs were 
shown to interact also by means of membrane vesicles called exosomes. The group of 
Mécheri reported experiments in which MCs lead to B cell activation, blast formation and 
IgM production without the need of MC-activation and physical contact (Tkaczyk et al., 
1996). These evidence led to the identification of exosomes, through which MCs mediate T 
cell-independent B cell activation (Skokos et al., 2001). 
Recently, it was shown that MCs can affect not only the B-cell effector function but also their 
regulatory properties.. Work published in our laboratory demonstrated that MCs can expand 
IL-10–competent B cells, but they do not directly induce IL-10 production; moreover, the 
absence of MCs negatively affects IL-10–competent B cell differentiation in vivo. 
Noteworthy, it has been demonstrated that the CD40L/CD40 axis plays a significant role in 
MC-driven expansion of IL-10–competent B cells in vitro and highlight the importance of 
MC CD40L signaling in the colon (Mion et al., 2014a). 
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1.1.5. Mast cells and tumors 
 
As reported by Hanahan and Weinberg, the hallmarks of cancer include ten mechanisms 
involved in tumor growth (Hanahan and Weinberg, 2011). One of these ten phases of cancer 
development is the inflammation step which faces the interaction of tumor-infiltrating 
immune cells with cancer cells and that plays a very important role in tumor progression. 
Among the tumor-infiltrating cells, MCs have been found to infiltrate the stroma of several 
tumors (Grivennikov et al., 2010). Although the study of the role of MCs in tumor 
progression is at the beginning, it is clear that MC-derived mediators can either exert pro-
tumorigenic functions, causing progression and spread of the tumor, or anti-tumorigenic 
functions, limiting tumor growth. 
Westphal was the first to suggest, in 1891, a pro-tumorigenic role for MCs after observing an 
increased number of MCs in diverse tumors, among which breast cancer, lip cancer, 
squamous cell carcinoma of the oesophagus, melanoma, multiple myeloma (MM) and lung 
carcinomas (Dabiri et al., 2004; Elpek et al., 2001; Ribatti et al., 2003; Rojas et al., 2005; 
Tataroǧlu et al., 2004). Nowadays, the observation of Westphal is corroborated by several 
studies reporting increased MC numbers both in hematologic and solid tumors. In certain 
types of tumors, MCs lead to a poor prognosis; this is the case of human lymphoid neoplasms 
such as Hodgkin´s lymphoma, B-cell non-Hodgkin’s lymphoma, primary cutaneous 
lymphoma and MM, and of solid tumors such as pancreatic cancer, hepatocarcinoma, prostate 
cancer and melanoma (Nico et al., 2008; Ribatti et al., 2000, 2003). On the other hand, in 
certain malignancies, MCs were shown to exert anti-tumorigenic effects, for example by 
supporting cancer rejection (Amini et al., 2007). In summary, what we know is that MCs 
infiltrate the tumor and that they can either promote or inhibit tumor growth depending on the 
specific setting. Moreover, MC infiltrates are often associated with tumor invasion and 
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increased microvessel density. All together, these studies on the role of MCs in the tumor 
context suggest to further explore these cells as possible diagnostic and therapeutic target of 
tumors. 
 
1.2. B CELLS 
 
B cells and their Abs are the central elements of humoral immunity and protect, as part of the 
adaptive immune system, against an almost unlimited variety of pathogens. In the human 
body, defects in B-cell development, selection and function lead to autoimmunity, 
malignancy, innumodeficiencies and allergy (Pieper et al., 2013). The B cell exerts three main 
functions: it presents Ag to T cells and it produces Abs and cytokines. In addition to their 
essential role in humoral immunity, B cells also mediate and/or regulate many other functions 
essential for immune homeostasis (Lebien and Tedder, 2008a). These cells have taken the 
name from the site where they were first discovered, the bursa of Fabricius, a primary 
lymphoid organ found only in birds and in which the process of B-cell maturation occurs. B 
cells can be distinguished from other lymphocytes, such as T cells and NK cells, for the 
presence of a membrane-bound protein known as B-cell receptor (BCR). This transmembrane 
receptor protein is composed of the CD79a/CD79b heterodimer and of a membrane-bound Ab 
that leads B cells to bind specific Ags. Once the Ag binds to the  BCR on the cell surface, it is 
internalized by receptor mediated endocytosis, processed and presented through the MHC 
class II to other cells (Marsh et al., 1992).  
As already mentioned, B cells can produce numerous cytokines that can be classified in 
effector and regulatory cytokines. Effector B cells can amplify humoral and cellular immune 
responses through the release of interleukin 2 (IL-2), IL-4, IL-6, IL-12, TNF-α, and 
interferon-γ (IFN-γ), whereas the regulatory cytokines are IL-10 and transforming growth 
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factor-beta (TGF-β) (Lund et al., 2005; Mizoguchi and Bhan, 2006). Interestingly, the 
production of IL-10 and TGF-β by B lymphocytes has led to the identification of a functional 
B-cell subset with immunosuppressive functions, which regulates the inflammatory response 
made up by T cells (Lebien and Tedder, 2008b). 
1.2.1. B-cell development and differentiation 
 
B cells develop from hematopoietic precursor cells in an ordered maturation and selection 
process. The hematopoietic system continuously regenerates all blood cells, indeed B 
lymphocytes are made continuously throughout life. This continuous process involves 
differentiation of the pluripotent HSC to more restricted progenitor cells, which undergo 
commitment to one of several pathways and then develop into mature cells of the selected 
lineage. One of the earliest steps in the hematopoietic development is the commitment of 
Multipotent Progenitors (MPP) to either the lymphoid or erythro-myeloid lineages, resulting 
in the formation of the Common Lymphoid Progenitors (CLPs) or Common Myeloid 
Progenitors (CMPs) (Fig.1.7). CLPs progenitors generate T lymphoid cells or B lymphoid 
cell. CLPs initiate the T cell lineages through early thymic progenitors (ETPs) and B cell 
lineages through pro-B cells. In this phases there are several factors that lead to either a T or 
B progeny. B-cell development depends on the transcription factors E2A, EBF and Pax5a. In 
the bone marrow, pro-B cells develop through pre-B cells into immature B cells. These 
translocate into the spleen to mature through transitional stages into mature B cells. 
 (Busslinger, 2004). 
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Figure 1.7. Overview of normal human hematopoiesis. Hematopoiesis originates from HMCs. Multipotent 
progenitors (MPPs) give rise to common lymphoid progenitors (CLPs) or common myeloid progenitors (CMPs). 
CLPs initiate the T cell and B cell lineages through early thymic progenitors (ETPs) and pro-B cells, 
respectively. In the bone marrow, pro-B cells develop through pre-B cells into immature B cells. These 
translocate into the spleen to mature through transitional stages into mature B cells. Modified from (Sauer and 
Cooke, 2010). 
 
 
B cell development occurs through several stages, each of which is characterized by a specific 
rearrangement of the DNA at the Ab loci. Pre and pro-B cells have low expression of the 
recombination-activating gene 1 (RAG-1) and RAG-2 genes (Oettinger et al., 1990; Schatz et 
al., 1989) and they do not express components of the BCR (Li et al., 1993). Pro-B cells are 
distinguished from earlier precursors by a series of cell surface markers: B220 (CD45), CD43, 
CD10, CD34 and CD19.  
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Figure 1.8 .B cell development from the pro-B to the immature B cell stage. The stages of B cell development 
are defined by the rearrangement status of the IgH and IgL chains. The expression of surface markers 
characterizing the different maturative stages are also indicated. Adapted from (Maier and Hagman, 2002). 
 
As progenitors progress through the pro-B stage, they express Terminal deoxinucleotide 
Transferase (TdT), RAG-1 and RAG-2 and, V(D)J recombination is initiated (Hardy et al., 
1991). Ig gene recombination begins with diversity (D) to junction (JH) segment 
rearrangement; then, in the late pro-B stage, VH (variable) genes become accessible to the 
V(D)J recombinase and complete heavy chain transcription units are assembled (Alt et al., 
1984). Expression of membrane-bound Igµ (mIgµ) results in assembly of the pre-BCR and 
marks the transition to the pre-B cell stage. The pre-BCR is composed of mIgµ and surrogate 
light chains (ψL, V-pre-B and λ5) and is a key checkpoint regulator in B-cell development 
(Karasuyama et al., 1990; Tsubata and Reth, 1990). Its primary functions are to trigger B cell 
differentiation, clonal expansion and heavy chain allelic exclusion. Indeed, the deletion of 
components of the pre-BCR blocks B cell development at the pro-B cell stage and 
lymphocytes are eliminated (Gong and Nussenzweig, 1996). After clonal expansion of 
mIgµ producers, pre-B cells arrest in G1. RAG and Igκ germline transcripts are expressed and 
pre-B cells undergo IgL chain gene recombination (Maki et al., 2000). Successful IgL chain 
gene rearrangement leads to BCR assembly and replacement of the ΨLs in the pre-BCR by 
Igκ or Igλ. Ig gene rearrangement can continue even after the assembly of functional BCRs. 
Apart from the expression of the pre-BCR receptor complex, the pre-B cell stage is 
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characterized, by a decrease in the expression of CD43, lack of TdT expression, and the 
successful rearrangement of the IgH locus. As these pre-B cells proceed through the 
differentiation process, the RAG genes are induced and IgL chain rearrangements begins 
(Henderson and Calame, 1998). Pre-B cells can be generally subdivided into large 
proliferating cells designated pre-BI (or large pre-B cells) and small postmitotic cells 
designated pre-BII (or small pre-B cells) on the basis of cell cycle analysis (LeBien, 2000). 
The completion of Ag-independent B cell development is marked by successful 
rearrangement of the IgL chain genes and expression of surface IgM. The cells then exit the 
bone marrow and migrate to the periphery. 
 
1.2.2. Maturation and activation of B cells 
 
When B cells leave the bone marrow they are still in an immature form; these cells have short 
life, high levels of IgM and low levels of IgD. The levels of IgM increase in näive B cells and 
these cells enter in peripheral lymphoid tissues when they receive the required signals for 
their survival (Thomas et al., 2006). Immature cells that survive to negative selection and 
migrate from the bone marrow to the periphery (initially to the splenic red pulp) are referred 
to as transitional B cells and they can be distinguished from mature B cells by several cell 
surface markers (Yu et al., 1999). In the spleen, transitional B cells receive signals that lead to 
their progression to Ab secreting cells. Specifically, in order to develop from the immature 
state in the bone marrow to the mature naïve state in peripheral lymphoid organs, a B cell 
must survive three checkpoints. The first checkpoint is between the immature cell and the 
transitional type 1 (T1) cell in the spleen. The second is between the T1 and the more mature 
T2/3 state, and the third is between the T2/ T3 stage and mature B cells. The nature of the 
BCR determines whether a B lymphocyte will become either a follicular (FO) or a marginal 
zone (MZ) B cell, a decision that is taken at the T2 stage (Pillai et al., 2005)(Pillai et al., 
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2005). Negative selection at each of these checkpoints is mediated by BCR signaling and is 
generally considered to be a B cell intrinsic property (Jacobi and Diamond, 2005). It has been 
demonstrated that a fundamental role in this process is also performed by BAFF (Fig. 1.9). In 
vitro studies found that treating mice with BAFF increased the number of splenic cells, in 
particular transitional B cells (Hsu et al., 2002; Moore, 1999). The effect of BAFF on B cell 
survival and longevity was limited to late transitional and mature B cells. Interestingly, the 
interaction of BAFF with its specific receptor BAFF-R is essential for survival of B cells in 
the transition from the T1 stage to the one of B2 cells, while only a minor contribution is 
given by the binding to TACI or B cell maturation antigen (BCMA) (Mackay et al., 2003). 
 
.  
Figura 1.9. BAFF-dependent maturation of murine B cells. B cell subsets circled in red require BAFF for 
development and survival. 
 
A role of BAFF and BAFF-R in the survival of B cells during B cell maturation was shown in 
BAFF- and BAFF-R- deficient mice, in which the maturation of MZ and B2 cells is impaired 
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beyond T1 stage (Pillai et al., 2005). Moreover, the production of BAFF and APRIL by non-
haematopoietic cells of local niches was shown to modulate the survival and function of B 
cells and plasma cells in health and disease. 
After B cell maturation, lymphocytes can bind the Ag and this leads to B cell activation. 
Activation of B cells can occur in a T-dependent manner, in which T cells have a central role, 
or in a T-indipendent manner in which other cells of the immune system mimic the role of T 
cells. T-independent activation occurs when B cells bind to thymus-independent (TI) Ags, 
which are divided in two categories, on the basis of their ability to stimulate an 
immunodeficient strain of mice, CBA/N, to produce Abs (Mond et al., 1978). T-independent 
type 1 (TI-1) Ags activate B cells without the need of a second signal, either in a polyclonal 
(prototype LPS) or an Ag-specific fashion (several viruses among which the vesicular 
stomatitis virus (Bachmann et al., 1995; Fehr et al., 1996). In contrast, T-independent type 2 
(TI-2) Ags need residual non-cognate T help for activation of B cells (polymeric Ags as 
dextran or bacterial polysaccharides (Mond et al., 1995)). TI-2 Ags have high molecular 
weight and they are characterized by highly repetitive structures. They are able to activate 
only mature B cells with the ability to aggregate the Ag receptor on the cell membrane. In 
particular, it has been demonstrated that TI-2 Ags affect a particular subpopulation of B cells 
called B1 (Murphy et al., 2009). Thymus-dependent (TD) Ags induce secondary immune 
responses characterized by IgG production due to specific T cell help. The interaction 
between B cells and T cells occurs in lymphoid organs: the Ag is recognized by the B cell via 
the BCR and then it is engulfed, processed and exposed on the surface of the cell thanks to 
MHC-II. In this manner, the peptide is recognized by T cells. This binding leads to B cell 
activation and to the secretion of several cytokines from the T
 
helper (Th) cell. The cognate 
activated T cell delivers important signals to the B cell through membrane-bound molecules. 
One of the most important interactions among co-stimulatory molecules is constituted by the 
CD40-CD40L axis which mediates specific T-cell help in response to TD Ags (Murphy et al., 
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2009). The importance of the CD40:CD40L axis is evident in the hypergammaglobulinemia 
X-linked hyper-IgM syndrome (HIGM) in which the CD40 gene is mutated. Indeed, these 
patients present defects in isotype switching and in the differentiation to plasma cells 
(Kawabe et al., 1994).  
In conclusion, in the development and maturation of B cells, the functional and protective end 
point is Ab production by terminally differentiated plasma cells. Ag-induced B cell activation 
and differentiation in secondary lymphoid tissues are mediated by dynamic changes in gene 
expression that give rise to the germinal center (GC) reaction (Fig. 1.10) (Lebien and Tedder, 
2008a). After the stimulation of B cells, which usually occurs in the GC of secondary 
lymphoid organs such as the spleen and lymph nodes, activated B cells begin to differentiate 
into more specialized cells. GC B cells may differentiate into memory B cells or plasma cells. 
The mechanism by which a B cell becomes one or the other of these is a process known as 
affinity maturation. Most of these B cells will become plasmablasts, and eventually plasma 
cells, and will begin to produce large amounts of Abs (Alberts et al., 2008). The GC is a site, 
within secondary lymphoid organs, where, during a normal immune response to an infection, 
mature B lymphocytes proliferate, differentiate, mutate their Ab genes (through somatic 
hypermutation, (SHM), of VH genes) and switch the class of their Abs through CSR. The GC 
develops dynamically after the activation of FO B cells by TD Ags (MacLennan, 1994). 
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Figura 1.10. Plasma cell differentiation. The binding of the Ag by B cells leads to B cell proliferation and 
differentiation. Upon stimulation by a T cell, which usually occurs GC of secondary lymphoid organs like the 
spleen and lymph nodes, the activated B cell begins to differentiate into more specialized cells. GC B cells may 
differentiate into memory B cells or plasma cells (Kuehl and Bergsagel, 2002). 
 
FO B cells are considered to be classical B-2 cells which respond to TD Ags, undergo GC 
reactions, and give rise to memory cells. MZ cells, which may also develop from FO B cells, 
are long-lived and have a partially activated phenotype. They have some features in common 
with B-1 cells in that they respond primarily to TI Ags and probably do not give rise to 
memory cells (Wang and Clark, 2003). 
 
1.2.3. B cells: class switch and somatic hypermutation 
 
Processes that diversify Abs play a major role in protecting higher organisms from pathogens. 
Upon encountering the Ag, Ab-expressing B cells adapt to produce a highly specific and 
potent Ab response (Hauser et al., 2008). Following Ag stimulation, naïve IgM+IgD+ B cells 
can undergo CSR to express and produce IgG, IgA or IgE (Tangye et al., 2006). After V(D)J 
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recombination, that, as explained above (see paragraph 1.2.1), in mammalian occurs in the 
bone marrow during early development, immature B cells move into peripheral lymphoid 
organs and Ag-activated B cells go through secondary Ab diversification by two DNA 
modification processes, CSR and SHM. CSR takes place in IgH switch (S) regions located 
upstream of the constant (C) region genes, while SHM occurs in variable (V) region genes 
(Chaudhuri and Alt, 2004; Di Noia and Neuberger, 2007). Both these two processes require a 
24 kDa enzyme called activation-induced cytidine deaminase (AID), that generates mutations 
in the DNA (Peled et al., 2008; Stavnezer et al., 2008). Specifically, this enzyme can induce 
two major alterations in Ig gene loci to enhance Ab and B cell function. First, the process of 
SHM introduces single point mutations at variables genes, increasing Ab affinity for the Ag 
(Longerich et al., 2006). Secondly, CSR replaces the Ig heavy chain constant region Cµ for 
Cγ, Cε or Cα and thereby controls the Ab effector function (Honjo et al., 2002). Initially, AID 
expression was thought to be limited to FO B cells of the GC (Muramatsu et al., 1999), but 
further studies have demonstrated that AID is active also outside the GC microenvironment 
(Mao et al., 2004). In mice, AID is induced by the CD40L:CD40 axis between T and B cells 
or by the binding of TLR4 by LPS (Nagaoka et al., 2010). These stimuli increase AID 
expression mainly through NF-kβ signaling (Xu et al., 2012). Several studies have 
demonstrated that cytokines produced by macrophages or DCs, such as TGF-β, IL-4, BAFF 
and APRIL, increase AID expression (Kim et al., 2007). The expression of AID is finely 
regulated under physiological conditions (Park, 2012) and this means that its aberrant 
expression can lead to the onset of tumors for genetic instability due to chromosomal 
translocations and point mutations. Because AID is responsible for both CSR and SHM, it 
may promote the development of autoimmune diseases by allowing the production of mutated 
autoreactive IgG B cells and autoreactive high affinity Abs (Durandy et al., 2013). Indeed, 
AID-deficiency in MRL/lpr mice abrogates lupus nephritis and a decrease in AID expression 
delays the development of such pathology (Jiang et al., 2007). It has been shown that 
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constitutive and ubiquitous expression of AID in transgenic mice caused both T cell 
lymphomas and dysgenetic lesions of epithelium of respiratory bronchioles (micro-adenomas) 
in all individual mice. Moreover, ectopic expression of AID could be partly responsible of 
malignancy in mice as well as in humans (Okazaki et al., 2003). Conversely, enzyme 
deficiencies are related to immunodeficiencies with loss of diversity of Igs (Quartier et al., 
2004). Several other pathologies can be exacerbated from AID aberrant expression: for 
example, in MM, this enzyme could play a very important role since a work from Bergsagel 
group underlined the possible correlation between ectopic AID expression and this pathology 
(Chesi et al., 2008).      
 
1.2.4. B cell populations 
 
B cells can be divided into different populations that are characterized by the differential 
expression of intracellular and cell surface markers. Among murine B cells, two distinct 
lineages, B-1 and B-2, can be identified. These cells have different developmental origin, 
anatomical localization and functional characteristics (Hardy and Hayakawa, 2001). In 
particular, B-1 cells are mainly located in body cavities (such as the peritoneal cavity) and, in 
a lower frequency, in the spleen. Conversely, B-2 cells are generally found in spleen and 
lymph nodes. B-1 cells can be divided into two population: B-1a cells, that are CD5+, and B-
1b cells that are CD5-. B-1a cells produce Abs against bacterial components while B-1b cells 
produce low affinity Abs in response to TI-2 Ags (Lebien and Tedder, 2008b). Among B-2 
cell we can find FO and MZ B cells. FO B cells circulate in the periphery and are able to 
produce high affinity Abs while MZ B cells constitute a non-circulating population that 
responds to immunogenic stimuli in TI manner. MZ B cells are a first line of defense against 
circulating Ags in the blood, they produce a limited repertoire of Abs but in a rapid manner. 
                                                                                                                                                Introduction 
 
 
For this reason MZ B cells and B-1 lymphocytes are defined “innate type lymphocytes” 
(Cerutti et al., 2013). 
Another B cell population that is important to mention is constituted by regulatory B cells 
(Bregs), which participate in immunomodulation and in suppression of immune responses 
(Lebien and Tedder, 2008a). These cells have elicited great interest in recent years, 
nevertheless the mechanisms regulating their induction and differentiation are still not clear. 
There are several mechanisms through which Bregs can exert their action and the production 
of IL-10 is certainly one of the most studied (Balkwill et al., 2013). IL-10 has strong anti-
inflammatory effects (Asseman et al., 1999) and it inhibits or suppresses inflammatory 
reactions mediated by T cells, especially Th1 type immune reactions. It is now clear that 
Bregs contribute to preserve immune homeostasis and they do so by modulating effector 
responses, both in contact-dependent and -independent manner. Indeed, the presence of 
different subsets of Breg cells, potentially distinct for their ontogenesis as well as for the 
differentiation and activation pathways, makes intriguing the study of these cells and gives to 
the immunologist the opportunity to investigate the development and regulation of immune 
system (DiLillo et al., 2010). On a more applicative perspective, the study of Breg cells could 
lead to the development of novel therapeutic approaches and to the understanding of the 
mechanism of action of biological drugs in inflammatory and autoimmune disease and cancer 
(Vitale et al., 2010). 
 
1.3. BAFF: B-CELL ACTIVATING FACTOR 
 
The immune system is a machinery of biological structures and processes that protects against 
disease. The different and several cell types composing the immune system orchestrate the 
immune response, fundamental for human life. In the immune system, the balance between 
cell survival and death is the basis of the controlled cell expansion in response to pathogens 
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and also in tissue homeostasis. When appropriate growth and survival signals are missing, 
most cells die. The control of cell survival is believed to involve the regulation of the anti-
apoptotic machinery (Plas et al., 2002). The elements that affect lymphocyte survival have 
been the focus of much attention in recent years. There are several cytokines that play a role 
in lymphocyte’s survival, one of this is BAFF. 
BAFF was identified for the first time in the late 1990s in a human neutrophil/monocyte-
derived complementary DNA library (Kalled, 2006; Mackay and Browning, 2002). Its 
discovery heralded a new understanding of B cell tolerance and differentiation and, 
consequently, of autoimmune diseases. Indeed, the blockade of BAFF constitutes a new 
therapeutic approach for the treatment of various pathologies, such as different autoimmune 
diseases (Sjögren’s Syndrome, SjS or Systemic Lupus Erythematosus, SLE) and some type of 
tumors (Mackay and Tangye, 2004; Moisini and Davidson, 2009). 
The gene encoding for BAFF is located on human chromosome 13q33.3 and contains 6 exons 
and 5 introns corresponding to 39 kb (Fig. 1.11 A). Instead, in the murine system, the gene of 
BAFF is mapped on chromosome 8 A1.1 and contains 7 exons and 6 introns corresponding to 
31 kb (Fig. 1.11 B) (Lahiri et al., 2012; Moore, 1999; Schneider et al., 1999).  
 
 
Figure 1.11. BAFF gene structure. A. Structure of the human gene of BAFF, constituted by 6 exons and 7 
introns. B. Structure of the murine gene, constituted by 7 exons and 6 introns (Lahiri et al., 2012). 
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This cytokine is also known as B lymphocyte stimulator (BLys) protein, TNF and apoptosis 
ligand-related leukocyte-expressed ligand-1 (TALL-1), zTNF4, CD257, TNFSF13B, TNF 
superfamily member (TNFS20) and TNF homolog that activates apoptosis, NF-kB and c-Jun 
NH2-terminal kinase (THANK) (Daridon et al., 2008; Lesley et al., 2004). Although initially 
believed to be produced solely by cells of the myeloid lineage, BAFF can be expressed also 
by cells of non-hematopoietic origin (Nardelli et al., 2001a). To date, it is known that BAFF is 
produced by monocytes, macrophages, neutrophils, DCs, activated T cells, FO DCs, splenic 
radiation-resistant stromal cells, astrocytes, fibroblast-like synoviocytes, nurse like cells 
osteoclasts and ductal epithelial cells (Kalled, 2006). In macrophages, BAFF represents the 
factor that more than others exerts a critical role on B cell biology (Craxton et al., 2003). It 
has been shown that, in the macrophage-like cell line RAW 264.7, its expression is increased 
after stimulation with TGF-β1 (Kim et al., 2008), and this is a critical event since TGF-β1 
also act as a powerful switching factor for IgA and IgG2b isotype switch (McIntyre et al., 
1993). 
1.3.1. BAFF structure 
 
BAFF is a member of the TNF family and it is composed of 285 amino acids (31,2 kDa) in 
humans and 309 amino acids (34,2 kDa) in mice. This cytokine is the natural ligand of three 
TNF receptors which are B cell maturation Ag (BCMA), transmembrane activator and CAML 
interactor (TACI) and BAFF receptor (BAFF-R) (Gross et al., 2000; Marsters et al., 2000). 
BAFF exerts several functions proper to the TNF-related cytokines, which are known to 
mediate host defense and immune regulation (Schneider et al., 1999). Indeed, TNF family 
members are defined as master switches in the immune system, controlling both cell survival 
and differentiation (Chicheportiche et al., 1997). In recent years, the TNF family has grown 
dramatically, to encompass at least 11 different signaling pathways that are involved in the 
regulation of the immune system (Kooten and Banchereau, 1997). This family is composed of 
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19 ligands and 29 receptors (Fig. 1.12), each of which plays a different role in the human 
body: proliferative activity, regulation of morphogeneses and control of apoptosis (Aggarwal 
et al., 2012). 
 
 
 
Figure 1.12. Members of the TNF family. Without exceptions, all members of the TNF superfamily exhibit pro-
inflammatory activity, in part through activation of NF-kB. Some of these molecules (OX40L, CD40L, CD27L, 
APRIL and BAFF) exert proliferative activity; EDA-A1, EDA-A2, TNF-α, FasL and TRAIL regulate 
morphogenesis, while TNF-α, TNF-β, FasL and TRAIL control apoptosis (Aggarwal et al., 2012). 
 
The members of this family exist in membrane-anchored forms, acting locally through cell-to-
cell contact, or as secreted proteins capable of diffusing to more distant targets (Vassalli, 
1992). Most TNF ligands are type II transmembrane proteins with extracellular domains that 
can be cleaved to generate soluble cytokines. These proteins are characterized by a short N-
terminal stretch most often constituted by short hydrophilic amino acids. This part is followed 
by a transmembrane region and an extracellular portion of variable length, that separates the 
C-terminal receptor binding domain from the membrane (Gruss and Dower, 1995). This 
particular extracellular region, that is proximal to the transmembrane part, is sometimes called 
the “stalk” (Richter et al., 2012). Figure 1.13 clearly shows the different domains that 
constitute BAFF protein: intracellular domain, transmembrane, stalk and extracellular 
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domain.  
 
Figure 1.13. Structure of BAFF. The intracellular domain is composed by 46 amino acids and it is followed by 
the transmembrane domain and by the stalk domain. Finally there is the TNF domain, that represents the 
extracellular part of BAFF (Schneider and Huard, 2010). 
 
BAFF shares roughly 20 to 30% similarity with other 16 members of the TNF family, namely 
TNF, LTα, LTβ, LIGHT, FasL, TRAIL, RANKL/ODF/TRANCE, TL1A/VEGI, 
GITRL/AITRL, EDA, TWEAK, CD40L, CD27L/CD70, CD30L,4-1BBL and OX40L and up 
to 50% similarity with A Proliferation-Inducing Ligand (APRIL), a ligand that has several 
biological activities in common with BAFF (Bodmer et al., 2002).  
BAFF displays typical features of type II transmembrane proteins, that can be cleaved by an 
enzyme belonging to the furin family of proteases (Nardelli, 2001; Schneider et al., 1999). 
Furin is a calcium dependent serine endoprotease that processes numerous proteins of 
different secretory pathways into their mature forms by cleaving at the carboxyl side of the 
recognized sequence. It has been shown that this endoprotease is mainly localized in the 
trans-Golgi network, although a part of the furin molecules cycle between this compartment 
and the cell surface (Nakayama, 1997). The furin cleavage sites are located on the N-terminal 
side of the TNF homology domain and permit the release of the soluble form of BAFF 
(Kanakaraj et al., 2001; Moore, 1999; Schneider et al., 1999). Therefore, BAFF can be found 
either in the 31-32 kDa membrane form (mBAFF) or in the 17 kDa cleaved or soluble form 
(sBAFF). The process of BAFF cleavage is very complex: several studies report that furin 
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cleaves the membrane-bound form of BAFF on cell surface and, in this way, the soluble 
molecule can be released. This mechanism of BAFF secretion was unequivocally 
demonstrated using a BAFF-transgenic mouse in which the full-length form was over-
expressed specifically in the liver. Soluble BAFF was detected in the blood and B cell 
hyperplasia was globally observed, indicating the transfer of soluble BAFF from the liver into 
organs in which the transgene was not expressed (Mackay et al., 1999). In general, cytokines 
of the TNF superfamily are functional both in their membrane-bound and in the soluble form 
(Bodmer et al., 2002). Cells expressing a non-cleavable membrane-bound form of BAFF, 
generated through an insertion mutation at the site of furin cleavage, were at least 50-fold 
more active than the soluble form of BAFF (Bossen et al., 2008). An alternative direct 
secretion pathway for BAFF has been described in neutrophils. In 2003, Scapini and 
coworkers showed that resting human neutrophils contain intracellularly both the unprocessed 
32 kDa mBAFF as well as the cleaved 17 kDa sBAFF. The exposure of neutrophils to 
cytokines such as G-CSF or IFN-γ leads to an increased accumulation of BAFF at 
intracellular level, but it is the subsequent exposure to stimuli such as LPS or TNF-α that 
induces a remarkable secretion of sBAFF. In an alternative way, the exposure to TNF-α 
induces the cleavage of mBAFF that generates extracellular sBAFF (Fig. 1.14) (Scapini et al., 
2008a). All together, these considerations have led to the conclusion that the process of BAFF 
production and release is strictly cell- and stimulus-dependent. 
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Figure 1.14. Regulatory mechanisms controlling sBAFF release in human neutrophils. The figure shows 
that in neutrophils both the unprocessed 32 kDa and the 17 kDa forms of BAFF are present. After exposure 
to G-CSF or IFN-γ there is an increase of novel synthesized BAFF and a partial release. A remarkable 
secretion of BAFF occurs when neutrophils stimulated with G-CSF or IFN-γ are exposed to pro-
inflammatory mediators such as TNFα or LPS. Instead, in resting neutrophils, the exposure to TNFα induces 
the cleavage of membrane-bound BAFF that generates soluble BAFF (Scapini et al., 2008b). 
 
The members of the TNF family usually assemble as trimers (Bodmer et al., 2002). BAFF 
was crystallized both as a trimer (BAFF 3-mer) and as a virus-like structure (BAFF 60-mer) 
(Fig.1.15). This virus-like structure is the result of the ordered assembly of 20 trimers 
(Karpusas et al., 2002; Liu et al., 2002). A work published in 2008 by Bossen and 
collaborators explained the different affinity of trimers and virus-like structures of BAFF to 
their receptors. They demonstrated that, in primary B cells, all forms of BAFF bind BAFF-R 
and TACI, eliciting BAFF-R dependent signals. In contrast, in plasmablasts or in mature B 
cells, the signaling through TACI was only achieved by higher disposal of BAFF oligomers. 
These data indicate that, despite BAFF-R and TACI can supply B cells with similar signals, 
only BAFF-R can respond to soluble BAFF 3-mer, that is the principal form found in 
circulation (Bossen et al., 2008). The unusual 60 mer form of BAFF is peculiar of this protein. 
Some experiments showed that the pH can affect the formation of BAFF trimers and 
aggregates. At pH equal to six, BAFF is found in its trimeric form, at pH equal to 6,5 the 
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oligomeric form begins to be detected, while at pH equal to 7,4 only the oligomeric form is 
present (Lahiri et al., 2012). It has been demonstrated that BAFF 60-mer was moderately 
more potent than the 3-mer form and, again, that the two different forms of this cytokine bind 
with different specificity to their receptors (Cachero et al., 2006).  
 
 
Figure 1.15. BAFF trimers and virus-like structure. The figure shows the two different structures of BAFF: 
BAFF 3-mer and 60-mer (Modified by Vincent et al., 2014). 
 
Similarly to most ligands of the TNF superfamily, BAFF is known to be a homotrimer. 
However, the possibility that BAFF could aggregate also with APRIL in a heterotrimeric form 
was suggested by structure analysis (Wallweber et al., 2004) and confirmed by the detection 
of BAFF/APRIL heterotrimers in the serum of patients with rheumatic disease (Roschke et 
al., 2002). Although these heterotrimers could bind all BAFF receptors, their specific 
functions are still unknown (Daridon et al., 2008). 
1.3.2. BAFF variants 
 
In addition to monomers, trimers and oligomers, BAFF can be found in various other forms 
and this renders even more intriguing the study of this cytokine (Lahiri et al., 2012). The 
complexity of the “BAFF world” is summarized in Fig. 1.16. At the genetic level, some 
BAFF polymorphisms (SNPs) have been observed and associated with various diseases. 
Concerning human BAFF, a polymorphism screening led to the identification of four of this 
in the promoter, one in intron 1 and a rare one in the coding region (Kawasaki et al., 2002). 
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Moreover, splicing variants of BAFF have been described. Ψ BAFF has been reported only in 
the human system and is the result of the incomplete splicing of intron sequences that leads to 
a non-functional transcript due to the appearance of a premature stop codon (Gavin et al., 
2003). Identified in 2003, ∆BAFF is an alternative splice isoform that lacks exon 3 in humans 
and exon 4 in mice. Some studies reveal that ∆BAFF suppresses BAFF function by 
competitive co-association, limiting BAFF homotrimerization. Moreover, it has been 
demonstrated that ∆BAFF and BAFF have opposing effects on B cell survival (Gavin et al., 
2005). Recently the discovery of a new transcriptional variant of BAFF has been reported: in 
humans we have ∆4BAFF and in mice ∆5BAFF, presenting the excision respectively of exon 
4 and 5. These splice variants can directly or indirectly regulate the differential expression of 
a large number of genes involved in the innate immune response and in the regulation of 
apoptosis (Lahiri et al., 2012). 
Finally, it is also important to mention that BAFF can present post-translational 
modifications, although these modifications have not been extensively studied. The only one 
described is the N-glycosylation: two sites for N-glycosylation are present in BAFF and are 
constituted by the asparagines at position 124 and 242 (Schneider et al., 1999).  
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Figure 1.16. Complexity of the “BAFF world”. BAFF can exist as oligomer, homotrimer and heterotrimer and 
also in a soluble or membrane-bound form. The existence of single nucleotide polymorphisms, glycosylation 
variants and isoforms renders extremely varied the world of BAFF (Lahiri et al., 2012). 
 
1.3.3. BAFF receptors 
 
As mentioned above, BAFF can bind to three receptors: BCMA, TACI and BAFF-R (Figure 
1.17). The three receptors have differing binding affinities for BAFF; moreover, TACI and 
BCMA also recognize APRIL, whereas BAFF-R is BAFF specific (Thompson et al., 2001). 
These receptors are expressed mainly on mature B lymphocytes and their expression varies 
depending on the specific B cell subset in analysis: while BAFF-R and TACI are expressed 
among transitional, FO and MZ B cells, BCMA is mainly present on long lived plasma cells 
(Cancro, 2006). The combination of the differential binding affinity and expression levels of 
these three receptors has the effect of making even more diverse the function of BAFF in 
relation to B cell biology. 
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Figure 1.17. Receptors of BAFF. The figure shows the three receptors that can bind BAFF and APRIL (Mackay 
et al., 2007a). 
 
TACI 
TACI can be found on different subsets of T cells and B cells, especially on activated B cells 
(Bülow and Bram, 1997). In mice it is expressed by all peripheral B cells and in particular on 
MZ and B-1 B cells while in humans it is expressed by all CD27+ memory B cells and by 
tonsillar and bone marrow plasma cells. This receptor plays critical roles in promoting B cell 
survival at distinct stages of development by engaging APRIL and/or BAFF. TACI controls T 
cell-independent B cell Ab responses, isotype switching and B cell homeostasis (Mackay and 
Browning, 2002; Mackay et al., 2003, 2007a, 2007b). TACI is an unusual TNF receptor-like 
molecule with a complicated mode of action. Experiments performed with TACI -/- mice 
revealed two apparently controversial roles of this receptor, a positive one driving T cell-
independent immune responses and a negative one down-regulating B cell activation and 
expansion (Mackay and Schneider, 2010). How TACI negatively regulates B cells remains 
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elusive and this makes even more complicated the understanding of BAFF signaling. 
However, an important role of TACI is to enhance plasma cell differentiation in cooperation 
with CD40 binding (Mantchev et al., 2007) and probably to control the activation and survival 
of plasmablasts derived from innate B cells and thus TI-2 humoral responses (Mackay and 
Schneider, 2010). 
 
BCMA 
BCMA is expressed on plasma cells, plasmablasts and tonsillar GC B cells (Laabi et al., 
1994). The function of this receptor is mainly limited to the survival of plasma cells residing 
in the bone marrow. However, among the three BAFF receptors, BCMA is the one whose role 
is more confusing. Although BAFF and APRIL can clearly bind to BCMA, (Thompson et al., 
2000) studies on BCMA-/- mice have shown that this receptor appears to be dispensable for 
humoral immune responses (Xu and Lam, 2001). Additionally, there is no direct evidence of 
BCMA cell surface expression on human lymphocytes since several evidences indicate the 
predominant expression of this receptor in the Golgi apparatus (Novak et al., 2004). 
 
BAFF-R 
BAFF-R is the only BAFF-specific receptor and it has the structure of a type II 
transmembrane protein (Bülow and Bram, 1997). This receptor is expressed on transitional 
and mature B cells in mice while in humans BAFF-R is widely expressed by all B cells except 
for bone marrow plasma cells (Mackay and Schneider, 2009). In particular, the BAFF/BAFF-
R pathway is crucial for the survival and growth of mature normal and malignant B cells. It is 
present on the plasma membrane but it is also found in the cellular cytoplasm, nuclear 
envelope and nucleoplasm (Fu et al., 2009). The expression of BAFF-R is not restricted to the 
B lineage as demonstrated by the evidence that a small subset of resting human and murine T 
cells present this receptor (Tangye et al., 2006). BAFF-R deficient mice show most of the 
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phenotypes of BAFF-deficient mice even if the absence of this receptor affects T cell-
dependent and -independent humoral responses less seriously, suggesting that BAFF-R 
transmits important BAFF signals which are although partially compensated by the other 
BAFF receptors in vivo (Bossen et al., 2008). The fundamental role of BAFF in the survival 
of B cells is evident in BAFF-R deficient mice, since in this mice the maturation of MZ and 
B-2 cells is strongly impaired beyond the T1 stage (Mackay et al., 2003).  
 
1.3.4. BAFF signaling 
 
In general, the receptors of the TNF family bind to proteins with a TNF receptor associated 
factor (TRAFs) domain. TRAFs are intracellular signaling molecules that are recruited to 
three receptors held in the correct geometry by a trimeric ligand. These proteins are able to 
induce survival and apoptotic signals. In particular, TRAF recruitment can activate two 
signaling pathways: the Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
kB) and the Mitogen-Activated Protein Kinase (MAPK) pathways. Specifically, the survival 
of B cells driven by BAFF is related to the induction of specific pathways associated with the 
activation of the NF-kB factor (Baud and Karin, 2001). When trimers of BAFF bind to 
BAFF-R we assist to the recruitment of TRAF3 that activates the alternative NF-κB2 
pathway. Conversely, when 60 mer BAFF binds to TACI there is the recruitment of TRAF2 
and TRAF6 that activate the classical NF-kB1 pathway (Fig. 1.18). The interaction between 
these pathways leads to ribosomic activation, mRNA transduction and finally to B cell 
survival and cellular growth (Mackay and Schneider, 2009). 
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Figure 1.18. BAFF signaling: When the various forms of BAFF bind to their receptors, the TRAFs pathways 
are activated. This leads to B cell survival (modifed from Mackay and Schneider, 2009). 
 
1.3.5. Role of BAFF on B cell biology 
BAFF plays a fundamental role in the immune system regulation because of its important role 
in B cell survival (Fig. 1.19). As already discussed in section 1.2.2 of this introduction, once 
B cells are generated in the bone marrow, they migrate to the spleen and they go through two 
intermediate stages called transitional type 1 (T1) and type 2 (T2), in order to complete their 
maturation process (Loder et al., 1999). Genetic analysis of the gain and loss of BAFF 
functions in mice show that the T2 stage is BAFF dependent, therefore this cytokine is very 
important for B cell survival and development. Transitional B cells cultured with BAFF 
acquire markers specific of mature B cells, demonstrating that BAFF may also be a 
maturation factor (Rolink et al., 2002). Conversely, data obtained in studies with BAFF 
deficient mice lead to conclude that BAFF does not seem to be essential for the development 
of B-1 cells (Batten et al., 2000). 
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Figure 1.19. B-cell maturation process. B cells coming from the bone marrow, enter the spleen and pass 
through two stages, T1 and T2, before maturity. To pass different stages they need a stimuli, one of this is BAFF 
(Mackay and Browning, 2002). 
 
BAFF was shown to have a co-stimulatory effect in standard B cell activation assays using 
anti-IgM Abs (Schneider et al., 1999). In these experiments, BAFF behaves similarly to IL-4 
or CD40L. However, BAFF alone does not induce B cell proliferation (Hsu et al., 2002). The 
crucial role of BAFF in B cell homeostasis has been established in experiments involving 
mice which over-expressed BAFF, since it was possible to observe B cell hyperplasia (Gross 
et al., 2000; Mackay et al., 1999). Moreover, Schneider and co-workers showed that mice in 
which BAFF was functionally blocked through the transgenic expression of the soluble form 
of TACI (TACI-Fc), presented a severe defect in mature B cells. The phenotype of TACI-Fc 
mice correlated with in vitro data implying that BAFF is a survival factor for transitional T2 B 
cells, pointing to a crucial role for BAFF in B cell development (Batten et al., 2000).    
 
1.3.6. BAFF in autoimmunity 
 
As previously described, BAFF is principally involved in B cell survival and maturation. 
When the level of this cytokine is “normal”, the B cell machinery works in the correct way. 
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Conversely, abnormal levels of BAFF may favor the survival and development of diverse B 
cell compartments, leading to autoimmune disease. Therefore, BAFF works as a double-
edged sword in B cell biology: on one side it is a fundamental factor for B cell development 
but, on the other, its overproduction contributes to the exacerbation of B cell-dependent 
diseases. The levels of soluble BAFF are increased in several autoimmune pathologies: high 
levels of this cytokine have been observed in sera and in target organs of murine models of 
SLE (Gross et al., 2000), collagen-induced arthritis (CIA) (Zhang et al., 2005a), rheumatoid 
arthritis (RA), SjS (Cheema et al., 2001; Groom et al., 2002) and in chemically induced 
autoimmunity (Zheng et al., 2005). Similarly, this occurs also in patients that have other 
different autoimmune diseases. In support, BAFF transgenic mice develop severe 
autoimmune symptoms that are similar to SLE and SjS in humans (Mackay et al., 2003). 
Disease development is associated with indiscriminate B cell survival (Bosello et al., 2008; 
George-Chandy et al., 2008; Mariette et al., 2003). Interestingly, the levels of BAFF are 
correlated with disease activity and titers of pathogenic auto-Abs (Table 1.3) (Mackay et al., 
2007a). 
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Table 1.3. Pathological role of BAFF in different diseases. (Mackay et al., 2007a)  
 
The contribution of BAFF to autoimmunity is confirmed by the therapeutic benefit gained by 
its neutralization. Indeed, lower or delayed levels of BAFF are detected in SLE-prone mice 
treated with TACI-Ig or BAFF-R-Ig fusion proteins, leading to the survival of these mice. 
TACI-Ig and BAFF-R-Ig affect mature FO and MZ B cells, without influencing the B-1 cell 
population (Gordon et al., 2003; Gross et al., 2000; Ramanujam et al., 2004, 2006). Moreover, 
BAFF antagonists conferred protection also in multiple sclerosis (Huntington et al., 2006) and 
in mice models of RA (Mackay et al., 2003; Wang et al., 2001). This last point is particularly 
relevant since, in patients with RA, the increased BAFF levels detected in the sera and 
synovial fluid may increase B cell survival; thus the neutralization of BAFF represents an 
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alternative therapeutic approach to target pathogenic B cells (Bosello et al., 2008; Ohata et al., 
2005). Nowadays, several Abs directed against human BAFF are used in clinical trials. One 
of these is a monoclonal Ab (mAb), called Tabalumab, that neutralizes both the membrane 
and soluble form of human BAFF (Genovese et al., 2013). As reported by Genovese and 
coworkers, Tabalumab reduced RA signs and symptoms with the same efficacy of the TNF 
inhibitors, routinely used in the treatment of this autoimmune disease (Genovese et al., 2013). 
RA is not the only pathology in which anti-BAFF mAb have been used. Another disease in 
which the blocking of BAFF is utilized as a therapy to solve autoimmunity is SLE. In the last 
50 years, no new drug for SLE has been approved; indeed, the last drugs accepted by the FDA 
were Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. The conventional therapy 
for this disease involves the use of drugs such as non-steroidal anti-inflammatory drugs, 
corticosteroids, anti-malarial agents, and immunosuppressant drugs that are aimed to reduce 
inflammation and unspecifically suppress the immune system (Doria and Iaccarino, 2013). 
Belimumab is a fully humanized mAb that binds to the soluble form of BAFF and inhibits its 
biological activity (Ding and Gordon, 2013). Belimumab was tested with good prognosis and 
represents a new expectation for all SLE patients, underlining the really important role of 
BAFF in this autoimmune disease (Specchia et al., 2014). 
 
1.3.7. BAFF in tumors 
 
In the medical field, BAFF has been studied above all for its role in B cell survival and for its 
consequent involvement in autoimmune diseases. In the last few years, the role of this 
cytokine has been investigated also in tumors. Indeed, there are different evidences that show 
how BAFF, and also APRIL, are involved in B cell malignancies such as Waldeström 
macroglobulinemia (WM), Hodgkin’s lymphoma (HL), non-Hodking’s lymphoma (NHL), 
chronic lymphocytic leukemia (B-CLL), and MM (Chiu et al., 2007; Elsawa et al., 2006; 
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Kern et al., 2004; Novak et al., 2002). This is demonstrated in transgenic mice which over-
expressed this cytokine, thus an increase incidence of B cell lymphomas was observed in each 
case (Batten et al., 2004). In humans, high levels of BAFF have been detected in sera and 
tumor microenvironment of patients that have various mature pathologies of the B cell 
lineage. However, cytokine expression has been detected in non-lymphoid breast cancer cells 
from epithelium origin (Pelekanou et al., 2008) and this evidence indicates that the role of 
BAFF in tumors might be more wide than first thought. In general, BAFF contributes to the 
survival of neoplastic B cells and this has important implications in oncology (Mackay and 
Tangye, 2004). BAFF can be produced by cancer cells (autocrine survival factor) or by the 
cells supporting tumor growth and constituting the tumor microenvironment niche (paracrine 
survival factor). This is particularly evident in NHL, where the aberrant production of BAFF 
by the malignant B cells themselves or by the supporting immune cells may facilitate their 
growth and survival (Tangye et al., 2006). In these pathologies, malignant B cells are all 
capable of binding soluble BAFF and this ability is functionally significant since in vitro 
experiments demonstrated that exogenous BAFF promotes the proliferation and/or the 
survival of B-CLL-, NHL-, MM- and WM-derived B cells (Elsawa et al., 2006; He et al., 
2004; Moreaux et al., 2003; Novak et al., 2002). Of particular interest is the role of BAFF in 
MM, an hematologic malignancy characterized by the accumulation of monoclonal plasma 
cells in the bone marrow (Tai et al., 2006). In almost all cases, MM is preceded by a 
premalignant disease, known as monoclonal gammopathy of undeteminated significance 
(MGUS) (Landgren et al., 2009; Weiss et al., 2009). The biological transition from normal 
plasma cells to MGUS and MM consists of many oncogenic events. An early event described 
in MGUS, as well as MM, is the dysregulation of a cycline D gene (Bergsagel et al., 2005). In 
the onset and development of MM two fundamental steps can be identified: the initiation 
phase, in which one clone of plasma cells acquire genetic alterations, and a progression phase, 
in which the complexity and alteration in plasma cells increased (Morgan and Kaiser, 2012). 
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Interestingly, Vacca and colleagues demonstrated that bone marrow microvascular density 
was significantly increased in MM compared to MGUS (Vacca et al., 1994). Moreover, to 
understand the biology of MM, one must study the bone marrow microenvironment that is 
made of a cellular compartment (stromal fibroblasts, osteoblasts, osteoclasts, endothelials 
cells and other immune cells) and a non-cellular compartment that includes the extracellular 
matrix and the liquid milieu, with cytokines, growth factors and chemokines (Ghobrial, 2012). 
Indeed, in MM, the bone marrow niche, plays an important role in differentiation, migration, 
proliferation, survival and drug resistance of the malignant plasma cells providing preclinical 
evidences for targeting MM cells and bone marrow stromal cells. Among the cytokines found 
in the tumor microenvironment, a relevant role is played by BAFF. It has been demonstrated 
that both myeloma cell lines and primary myeloma cells express BAFF and their receptors 
(Moreaux et al., 2004) and that BAFF can lead to the survival of malignant plasma cells in 
myeloma, playing an important role in tumor progression and sustenance (Novak et al., 2004) 
For these reasons, in MM, BAFF could represent a potential diagnostic factor and, above all, 
a possible target towards which drug therapy could be directed. 
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2. AIMS OF THE WORK 
 
The MC is a cell of the immune system well known for its role in allergy and in the defense 
against pathogens. Recent studies have shown that MCs play also an important role in the 
homeostasis of the immune system by interacting with different immune cell types (Gri et al., 
2012). Defined by Frossi and colleagues as “the antenna of the microenvironment”, in recent 
years it has been shown that the MC is not only implicated in allergy, but it is also involved in 
several processes in the immune system (Gri et al., 2012). Therefore, MCs have a versatile 
physiological function and they should no longer be considered simply as “allergic cells” 
(Garfield et al., 2006; Maurer et al., 2004). MCs can interact with other cell types and this 
renders the study of the role of these cells increasingly complex and prominent. Finally, MCs 
have also a role in tumors, although their specific mechanism of action is not yet clear. 
B cells require multiple and diverse signals for their development and differentiation in 
effector cells. Depending on the nature of the Ag and of the second signal, B cells can be 
activated in a T cell-dependent or -independent manner. Previous work done in the laboratory 
in which this project was performed, demonstrated that MCs are able to activate B cells and 
regulate their effector functions. Indeed, MCs enhance B cell proliferation and drive their 
differentiation towards IgA secreting plasma cells. A fundamental role in the interaction 
between MCs and B cells is played by the CD40/CD40L axis, but also soluble factors are 
involved (Merluzzi et al., 2010).  
It has been recently demonstrated that neutrophils, through the production of BAFF, provide 
fundamental stimulating signals to the B cell, including signals activating CSR and SHM 
(Mackay and Browning, 2002). Therefore we were interested in assessing whether BAFF 
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could be a previously unknown element linking the interaction between MCs and B cell and 
the processes of CSR and SHM.  
Starting from these considerations we have investigated the presence of BAFF on MCs and its 
involvement in the B/MC interaction. In the first part of this study, the experiments were 
designed in order to assess whether MCs could produce BAFF. After that, the work was 
focused on the understanding of the role of BAFF in the context of B/MC interaction, both in 
physiological and pathological states. In light of the discovery of increased MC numbers in 
MM (Ribatti et al., 1999) and of the important role played by BAFF in this B cell malignancy 
(Groom et al., 2002; Haiat et al., 2006) , we decided to study the involvement of MC-derived 
BAFF in the context of MM. 
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3. RESULTS AND DISCUSSION 
 
3.1. INVESTIGATION OF BAFF PRODUCTION IN MAST CELLS 
 
3.1.1. BAFF gene expression in murine and human MCs 
 
It is now well established that defining the MC as a mediator of the allergic response is 
definitely an understatement given the growing body of evidence underlining the pivotal role 
of this cell in the protection against pathogens and in the regulation of both innate and 
adaptive immunity (Gilfillan and Beaven, 2011). An important role in MC ability to modulate 
the immune response is played by the crosstalk between members of the TNF superfamily and 
their receptors. Several studies have shown the importance of the direct interaction between 
MC-expressed OX40L and T cell OX40 in the induction of T cell proliferation (Jun-ichi 
Kashiwakura, Hidenori Yokoi, 2004; Nakae et al., 2006), and in the inhibition of Treg 
suppressive activity, and consequent Th17 cell differentiation (Piconese et al., 2009). In the 
context of the B cell-MC crosstalk, a key role is played instead by the CD40-CD40L 
interaction which not only promotes B cell survival and proliferation but also contributes to 
MC-driven expansion of IL-10-competent B cells (Merluzzi et al., 2010; Mion et al., 2014b). 
Similarly to other TNF family ligands, BAFF is a type II transmembrane protein that plays a 
fundamental role in B cell development and survival (Mackay et al., 2003). Although the 
GeneChip data of a study conducted by Mackay’s group in 2004 showed that transcripts of 
BAFF were expressed in MCs (Ng et al., 2004), no one, to our knowledge, has ever examined 
in depth such result. In order to better elucidate the regulation of BAFF production in MCs, 
we decided to first examine BAFF gene expression in both murine and human MCs at the 
mRNA level. Concerning the murine setting, levels of endogenous BAFF transcripts were 
assessed by reverse transcriptase polymerase chain reaction (RT-PCR), both in wild type bone 
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marrow-derived MCs (BMMCs wt) and in the mouse MC/9 MC line. In parallel, the 
experiment was performed with the murine macrophage-like cell line RAW 264.7, which has 
been reported to express BAFF gene under basal conditions (Kim et al., 2008), and in BAFF-
deficient BMMCs (BMMCs baff -/-). As shown in Fig. 3.1, both wt BMMCs and MC/9 
expressed sufficient BAFF mRNA to give a positive signal although the intensity of the bands 
were weaker compared to the RAW 264.7 condition. Consistently, no PCR product was 
instead observed for the negative control condition, represented by BAFF-deficient BMMCs. 
 
Figure 3.1. BAFF gene expression in murine MCs. The presence of BAFF mRNA was determined by RT-PCR 
in wild type (BMMC wt) and BAFF-deficient (BMMCs baff -/-) MCs and in the murine cell lines MC/9 and RAW 
264.7. RAW 264.7 and BAFF-deficient MCs (BMMCs baff -/-) represent respectively the positive and negative 
controls. Control amplifications (G3PDH) are also shown. Images are representative of results from at least 
three independent experiments. 
 
In order to have a quantitative measurement of BAFF gene expression, experiments of real 
time PCR (qPCR) were performed and results were expressed as fold induction compared to 
the wt BMMCs condition (Fig. 3.2). The levels of BAFF mRNA expression were about three 
times higher in RAW 264.7 than in wt BMMCs, indicating that, under basal conditions, MCs 
might produce lower amounts of BAFF compared to macrophages. 
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Figure 3.2. Murine MCs express BAFF mRNA. The relative level of BAFF mRNA was determined by qPCR in 
wild type (BMMCs wt) and BAFF-deficient (BMMCs baff -/-) MCs and in the murine cell lines MC/9 and RAW 
264.7. RAW 264.7 and BMMCs baff -/- represent respectively the positive and negative control. In all tested 
conditions the expression levels are shown as fold induction over wt BMMC. The G3PDH transcript levels were 
used to normalize samples. Results of three experiments for wt, baff-/-, RAW 264.7 and two experiments for MC/9 
are shown as mean values plus SEM. 
 
Since murine and human MCs share several similarities but also present some differences 
(Bischoff, 2007), we decided to investigate whether the result relative to BAFF expression 
could stand true also in the human system. Unfortunately, it is not easy to obtain and work 
with primary human MCs (Guhl et al., 2010) and therefore the experiments were performed 
using two different human MC lines, HMC-1.2 and LAD2, which are extensively used despite 
their many limitations. As for the murine system, human BAFF gene expression was assessed 
through both RT-PCR and q-PCR, using the human cell lines U937 and HEK 293, 
respectively as positive and negative controls (Daridon et al., 2007). Both techniques 
demonstrated that BAFF transcripts levels were higher in HMC-1.2 than in HEK 293 cells 
(Fig. 3.3A, B). Also LAD2 cells resulted positive in comparison to the negative control 
although the levels of BAFF expression seemed much lower than the ones detected in HMC-
1.2 cells (Fig. 3.3A, B). 
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Figure 3.3. BAFF gene expression in human MCs. (A) A representative RT-PCR analysis and (B) the 
quantitative real time PCR result of n=3 independent experiments are presented for both the HMC-1.2 and the 
LAD2 cell lines. U937 and HEK 293 cells served respectively as positive and negative controls. 
 
3.1.2. Effects of IgE-dependent and -independent MC-stimulation on BAFF 
expression 
 
After confirming BAFF gene expression under basal conditions in both human and murine 
MCs, we further investigated if BAFF transcript levels were affected by the addition of 
stimuli known to affect the biology of the MC. Indeed, several reports described a variation of 
BAFF expression and production in response to cell stimulation. The kind of variation was 
shown to be cell- and stimulus-dependent: while RAW 264.7 were shown to increase BAFF 
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production following stimulation with either IFN-γ or TGF-β (Kim et al., 2008), neutrophils 
were reported to dramatically activate the novel synthesis of BAFF in response to G-CSF or 
IFN-γ (Scapini et al., 2003).  
The particular nature of the MC renders this cell type particularly sensitive to activation by 
means of several and different kind of stimuli, not necessarily related to the binding of the 
IgE-Ag complex by FcεR. Although a variety of classical MC agonists could up-regulate 
BAFF gene and protein expression, we decided to test the effect of the classical IgE/Ag 
stimulation and of LPS and IFN-γ, which have been both related to BAFF production by DCs, 
macrophages, and activated T cells (Huard et al., 2004). Murine MCs were cultured for 5 h in 
the presence or absence of the aforementioned stimuli before being collected and lysed for 
RNA extraction. As shown in Fig. 3.4, no significant variation in BAFF gene expression was 
observed in either BMMCs (panel A) or in MC/9 (panel B) after treatment with IgE/Ag, IFN-
γ or LPS, indicating that these stimuli alone are not able to affect the basal expression of 
BAFF observed in murine MCs. A similar outcome resulted also from HMC-1.2 (panel C) 
and LAD2 (panel D) stimulation, although an increase in BAFF gene expression (which did 
not reach statistical significance) was observed for IFN-γ-stimulated HMC-1.2. 
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Figure 3.4. Effect of MC-stimulation on BAFF expression. BMMCs (A) and the MC/9 (B), HMC-1.2 (C) and 
LAD2 (D) cell lines were cultured with medium alone or stimulated for 5 h with IFN-γ, LPS or through FcεR, as 
described in the materials and methods section. Cells were lysed for RNA extraction and BAFF expression was 
assessed by qPCR. In all tested conditions the expression levels are shown as fold induction over unstimulated 
MCs (NST). Reported results show means (± SEM) from at least three independent experiments for BMMC, 
MC/9 and HMC-1.2, and n=2 experiments for the LAD2 condition. 
 
3.1.3. APRIL gene expression in MCs 
 
As already mentioned in the introduction of this thesis, APRIL is a TNF ligand with close 
homology to BAFF, with which it shares several functions within the B cell arm of the 
immune system (Ng et al., 2005). While the full-length form of BAFF is cleaved 
preferentially at the cell surface, APRIL is processed inside the cell by a furin-convertase and 
is able to exert its function only as a soluble factor (Daridon et al., 2008). The important role 
                                                                                                                                Results and discussion 
 
 
of APRIL, together with its relation to BAFF, makes the study of this protein very interesting. 
Thus, we decided to assess whether this cytokine could be produced by murine MCs. 
Since we did not have the possibility to work with APRIL-deficient BMMCs, the level of 
APRIL gene expression in MCs was compared with those of cell types for which the 
production of this cytokine has not been described in literature. As shown in Fig. 3.5 APRIL 
transcripts were detectable under basal conditions in BMMCs but not in murine C2C12 
myoblasts (Fig. 3.5A) and in the A20 B cell lymphoma line (Fig. 3.5B). 
 
 
Figura 3.5. Murine MCs express APRIL mRNA. The relative level of APRIL mRNA was determined by qPCR 
in BMMCs and C2C12 (A) and in BMMCs, A20 cell line and unstimulated B cells (B). C2C12, A20 and 
unstimulated B cells present the negative control. In all tested conditions the expression levels are shown as fold 
induction over BMMCs. The G3PDH transcript levels were used to normalize samples. Results of two 
independent experiments for A panel and one for B panel. The experiments are shown as mean values plus SEM. 
 
Furthermore, the effect of IgE/Ag, LPS and IFN-γ stimulation was tested both in BMMCs 
and in the MC/9 cell line. Contrary to what observed in the case of BAFF expression, for 
which there was no difference in the presence or absence of stimulation, LPS decreased 
APRIL transcript levels, in both BMMCs and MC/9, while IgE/Ag activation augmented the 
expression of this cytokine in MC/9 cells (Fig. 3.6). Although these results need to be studied 
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in more detail, they constitute a good starting point for future investigations regarding the role 
of this cytokine in the B/MC crosstalk. 
 
 
Figure 3.6. APRIL gene expression following MC-stimulation. BMMCs (A) and MC/9 (B) were cultured with 
medium alone or stimulated with IgE/Ag, IFN-γ or LPS for 5 h. APRIL gene expression was assessed by qPCR 
and the G3PDH transcript levels were used to normalize samples. In all tested conditions the expression levels 
are shown as fold induction over unstimulated MCs (medium). Reported results show means (± SEM) from at 
least three independent experiments. 
 
3.1.4. Full-length BAFF production by MCs 
Transcription level data can give information whether or not a protein of interest is present in 
a cell. In light of the results obtained at the mRNA level, we decided to deepen the study of 
BAFF expression in MCs and focus on protein production. 
We first analyzed BAFF synthesis in the murine context, by western blot analysis. 
BMMCs and RAW 264.7 cells were collected, washed twice with ice-cold PBS and incubated 
for 30’ at 4°C, under gentle rotation, with 1% NP-40 in lysis buffer. Whole cell extracts were 
quantified through Bradford assay and resolved by 12% SDS gel electrophoresis, before being 
probed with anti-BAFF and anti-tubulin Abs. Both in the RAW 264.7 and BMMC samples, 
the immunoblot analysis revealed the presence of a protein band in correspondence of the 
expected molecular weight of the full length form of BAFF (31-35 kDa), confirming the 
production of BAFF protein by murine MCs (Fig. 3.7A). Similarly, western blot analysis was 
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performed on lysed samples of HMC-1.2 and LAD2 MCs and of U937 and HEK 293 cells, 
which served respectively as positive and negative controls. As shown in Fig. 3.7, BAFF 
protein was detected in total lysates from U937 cells and, to a lesser degree, in that from 
HMC-1.2 (panel B) and LAD2 (panel C) cells. 
 
Figura 3.7. Representative WB images of BAFF expression in murine and human MCs.The protein samples 
from the indicated cells in murine system(A)and human system (B,C) were detected by Western Blotting using 
murine and human anti-BAFF. BAFF protein in murine cells (about 35 kDa band) in human cells (about 31 kDa 
band), tubulin (55 kDa band)was used a control for equal loading of cell lysates.   
 
Production of full-length BAFF was further validated by confocal microscopy analysis of 
BMMCs, which showed the presence of this cytokine mostly at the level of cell membrane 
(Fig. 3.8). The specificity of BAFF staining was checked by comparing wt (upper panel) and 
BAFF-deficient (lower panel) BMMCs. 
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Figure 3.8. Representative confocal images of BAFF expression in murine MCs. Immunofluorescence 
analysis on wt BMMCs was performed using a FITC-labeled anti-BAFF Ab to identify BAFF-positive cells. 
BAFF-deficient MCs (baff -/- BMMCs) served as negative controls for BAFF staining. All picture were taken 
under 63x magnification. Bar = 10 µm. 
 
3.1.5. Regulation of membrane-bound and soluble BAFF production in MCs 
In most cell types, BAFF is localized on the cell membrane where it can be cleaved by a 
furin-like protease, to generate the soluble form of this cytokine. However, it has been shown 
that the soluble form can be also produced by the cleavage of full length BAFF that occurs 
intracellularly (Scapini et al., 2003), broadening the complexity of BAFF investigation. In 
addition, several studies have reported a different potency of membrane-bound and soluble 
BAFF. Although in the past soluble BAFF was believed to be the predominant form of this 
protein, in 2008 Schneider’s group demonstrated that cells expressing a non-cleavable 
membrane-bound form of BAFF were at least 50-fold more active than soluble BAFF at 
delivering signals to responder cells (Bossen et al., 2008). The evidence that the membrane 
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form can have distinct roles compared to the soluble form has also been reported by a recent 
study showing that depending on the context, membrane-bound BAFF can be a more potent 
stimulus than cleaved soluble BAFF (Manetta et al., 2014). In light of all this evidence, we 
decided to investigate the production of the two different forms of BAFF by MCs, under basal 
conditions. 
The expression of membrane-bound BAFF was assessed by flow cytometry analysis, in 
both the murine and human setting. Regarding BMMCs, protein expression was analyzed in 
wt and baff -/- MCs and revealed the presence of a marked difference between the two 
conditions (Fig. 3.9A). However, similarly to the co-stimulatory molecule CD40L (Merluzzi 
et al., 2014), the expression of BAFF seemed to vary based on the specific BMMC culture in 
analysis (differentiation stadium, age of culture, heterogeneity of precursor cells, which may 
vary from mouse to mouse, etc.). Indeed, as shown in Fig. 3.9B, MCs deriving from three 
different BMMC cultures produce different amounts of BAFF. 
 
 
Figure 3.9. Flow cytometry analysis of membrane-bound BAFF expression in human MCs. (A) Surface 
expression of BAFF was analyzed by flow cytometry on wt (black histogram) and baff -/- (red histogram) bone 
marrow MCs, using a FITC conjugated anti-murine BAFF Ab (clone Buffy-2). The filled histogram represents 
the unstained sample. A representative histogram is shown here for three independent experiments. (B). BAFF 
expression levels in three different BMMC cultures are compared. As a control, the baff -/- condition is reported. 
 
Concerning the human system, membrane-bound BAFF was analyzed both in the HMC-1.2 
and in LAD2 cell lines, using U937 and HEK 293 cells as positive and negative controls 
respectively. In accordance with previously published data (Nardelli et al., 2001b), U937 cells 
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expressed high amounts of cell-surface BAFF while the cytokine was present at lower levels 
on HMC-1.2 and LAD-2. Nevertheless, BAFF staining on human MCs was positive 
compared to the HEK 293 negative control cell line (Fig. 3.10). 
 
 
 
Figure 3.10. Flow cytometry analysis of membrane-bound BAFF expression in human MCs. The U937 (blue 
histogram), LAD2 (red histogram), HMC-1.2 (black histogram) and HEK 293 (grey filled histogram) cell lines 
were stained with a PE conjugated anti-human BAFF Ab (clone 1D6) and analyzed for BAFF expression on the 
cell membrane. A representative histogram is shown here for three independent experiments. 
 
Once demonstrated the expression of membrane-bound BAFF by both murine and human 
MCs, we moved to the study of the soluble form of this cytokine. With this aim, cell 
supernatants were collected from both wt and baff -/- MCs which were cultured for 48 h in 
medium without IL-3; then BAFF concentration was determined through ELISA. 
Interestingly, resting BMMCs were not able alone to produce soluble BAFF since no 
differences were observed compared to the knock-out condition (Fig.3.11A). Similarly, the 
amounts of soluble BAFF released by HMC-1.2 and LAD2 cells were almost undetectable 
and comparable to the negative control condition, that is HEK 293 cell supernatant (Fig. 
3.11B). These results prompted to further investigate the process of BAFF release and assess 
the relevance of MC-stimulation in this experimental setting. Indeed, several works have 
shown that BAFF release into the external fluids is stimulus-dependent (Scapini et al., 2008b). 
Both wt and baff -/- BMMCs were cultured for 48 h in the presence or absence of different 
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stimuli known to be related to an increase of BAFF production (LPS, IFN-γ, LPS+IFN-γ). 
However, once again, the levels of BAFF detected in cell supernatants did not change 
compared to the baff -/- condition, even following cell stimulation (Fig. 3.11C). 
All together, these data suggest that membrane-bound but not soluble BAFF is produced 
by resting MCs, which require a specific, and not yet identified, signal to promote the release 
of this cytokine. 
 
 
Figure 3.11. MCs do not produce soluble BAFF. (A) For measuring secreted BAFF, culture supernatants from 
wild type (wt) and BAFF-deficient (baff -/-) BMMCs were harvested after 48 h of culture in medium without IL-3 
and BAFF concentration was measured by ELISA. The culture supernatant of LPS-stimulated neutrophils was 
used as positive control. (B) The soluble form of human BAFF was measured in cell supernatants of HMC-1.2, 
LAD2, U937 and HEK 293 cells which were cultured for 48 h under basal conditions. (C) The production of 
soluble BAFF was measured in wt and baff -/- MCs after stimulation with either LPS, IFN-γ or LPS+ IFN-γ for 
48 h. (A, B, C) All reported results are from a representative experiment. 
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3.2. ROLE OF MC-PRODUCED BAFF IN THE B/MC CROSSTALK 
 
3.2.1. MC-expressed BAFF promotes B cell survival 
 
Over the last decade, several studies have shown that MCs are important regulators of B cell 
biology and that they exert their function by producing several cytokines and expressing 
important co-stimulatory molecules (Merluzzi et al., 2014). After demonstrating BAFF 
expression in MCs and its production mainly as a cell-surface protein, the next step was to 
understand the role of this cytokine in the crosstalk between B cells and MCs (B/MC). Since 
one of the most important roles of BAFF is to enhances B cell survival (Mackay and 
Browning, 2002), our first aim was to assess the contribution of BAFF to MC-induced B cell 
survival. 
To test the effect of MC-expressed BAFF on B cell viability, freshly purified splenic B 
cells were cultured alone or with either unstimulated or IgE-Ag-stimulated MCs, in a 1:1 
ratio. To block the possible interaction between BAFF on MC-surface and its receptor on B 
cells, the B/MC co-culture condition was set up in the presence or absence of a recombinant 
mouse TACI-Fc chimera. Since BAFF leads to the survival of B cells (Mackay et al., 2003), 
BAFF-stimulated B cells were used as positive control of the experiment. After 48 h of co-
culture, cells from each condition were collected, washed with PBS and stained with an anti-
CD19 mAb in order to discriminate B cells from MCs. Finally, staining with annexin V and 
propidium iodide was required to discriminate viable from necrotic or apoptotic B cells 
Figure 3.12 shows a representative analysis of the flow cytometry data and the gating strategy 
performed to exclude the MC from the analysis of B cell viability. 
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Figure 3.12. Gating strategy and flow cytometry analysis for the identification of viable B cells in the B/MC 
co-culture. Using the CD19 vs SSC plot (left panel) it is possible to select only the B cell fraction and exclude 
MCs from the analysis. Percentages of necrotic (AnnexinVneg Propidium Iodide pos), late apoptotic (AnnexinVpos 
Propidium Iodide pos), early apoptotic (AnnexinVpos Propidium Iodide neg) and viable (AnnexinVneg Propidium 
Iodide neg) cells were assessed by flow cytometry after cell staining with annexin V and propidium iodide (right 
panel). Flow cytometry plots from one representative experiment are shown. 
 
As expected, compared to the condition in which B cells were cultured alone, B cell viability 
increased both in the presence of recombinant murine BAFF and of resting or IgE/Ag 
activated MCs (Fig. 3.13A). Interestingly, in the presence of TACI-Fc a slight although 
significant reduction of viable B cells was observed with resting but not IgE/Ag stimulated 
MCs.(Fig. 3.13A). To further investigate these findings, we used BMMCs derived from baff -/- 
mice to set up the B/MC co-culture. As shown in panel B of Fig. 3.13, consistently with the 
experiment performed using TACI-Fc, a decrease of the percentage of viable cells was 
observed using BAFF-deficient MCs, reduction that reached statistical significance in the case 
of resting (30% decrease) but not IgE/Ag (20% decrease) stimulated MCs. Collectively, these 
data lead to the conclusion that the contribution of BAFF to MC-induced B cell survival is 
particularly relevant in the case of resting MCs, where this cytokine might act together to 
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other co-stimulatory molecules to ensure the optimal function of MCs. Conversely, the role of 
membrane-bound BAFF might become secondary in the case of the co-culture between B 
cells and IgE/Ag stimulated MCs, a condition in which the action of BAFF is hidden by other 
cytokines released by activated MCs which are known to be important physiological 
stimulators of B cell growth and survival. 
 
 
Figure 3.13. BAFF plays a significant role in B cell survival induced by resting murine MCs. (A) B cell 
viability was analyzed through Annexin V/Propidium Iodide assay in B cells cultured for 48 h either alone 
(Medium) or with non-sensitized MCs (MC) or IgE-sensitized MCs stimulated with DNP (MC IgE/DNP). TACI-
Fc (1µg/ml) was added to the co-culture system in order to evaluate the role of BAFF (MC + TACI-Fc; MC 
IgE/DNP + TACI-Fc). B cells cultured with BAFF (1µg/ml) served as positive control. Bar graphs indicate 
mean (± SEM) percentages of viable B cells among total B cells from n = 6 independent experiments. (B) The 
role of BAFF was assessed using baff -/ -MCs and LPS (10µg/ml)-stimulated B cells served as positive control. 
Bar graphs indicate mean (± SEM) percentages of viable B cells among total B cells from n = 4 independent 
experiments. 
 
The obtained results prompted us to assess whether MC-expressed BAFF was able to 
induce B cell survival also in the human system. With this aim, CD19+CD21+IgM+ B cells 
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were isolated from the peripheral blood of healthy donors and cultured with HMC-1.2 cells 
for 48 h. As shown in Fig. 3.14 the staining and gating strategy is analogous to that developed 
for the murine system and required the consequential incubation with an a-human CD19 mAb 
and with annexin V and propidium iodide. Although the experiment was not repeated 
sufficient times in order to perform a statistical analysis, the data reported in Fig. 3.14 clearly 
show how HMC-1.2 cells lead to B cell survival, since the percentage of viable cells is 
increased from about 7% (B NST) to 60% (B NST+HMC-1.2). Remarkably, the percentage of 
viable cells decreases to about 52% when human TACI-Fc is added to the HMC-1.2/B cell 
co-culture. This result confirmed the data deriving from the murine system and reinforce the 
conclusion that BAFF takes part to MC-induced B cell survival. 
 
Figure 3.14. BAFF is involved in B cell survival induced by HMC-1.2 cells. B cell viability was analyzed 
through Annexin V/Propidium Iodide assay in CD19+CD21+IgM+ cells isolated from peripheral blood and 
cultured for 48 h either alone (B NST) or with HMC-1.2 cells (B NST + HMC-1.2). Human TACI-Fc (5µg/ml) 
was added to the co-culture system (B NST + HMC-1.2 + TACI-Fc) in order to evaluate the role of BAFF. Flow 
cytometry plots from one representative experiment are shown. 
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3.2.2. MC-expressed BAFF promotes B cell proliferation 
 
BAFF is best known for its role in the enhancement of B cell maturation and survival, 
however, the interaction of this cytokine with its receptor was shown to be significant also for 
B cell proliferation, especially in the case of aggressive B lymphocytes (Liang et al., 2014). 
MCs were proved to be able to induce a significant increase of naive B cell proliferation, a 
process dependent on cell-cell contact and MC-derived IL-6 (Merluzzi et al., 2010). 
Therefore, our next aim was to establish whether MC-expressed BAFF could contribute to the 
induction of B cell expansion. For this purpose, both for the murine and human system a 
proliferation assay based on cell labeling respectively with carboxyfluorescein succinimidyl 
ester (CFSE) and 5-bromo-2-deoxyuridine (BrdU) was set up. 
Concerning the murine B cell proliferation assay, B lymphocytes were purified from 
mouse spleen, stained with CFSE and cultured for 72 h alone or in the presence of either wt or 
BAFF-deficient MCs. Fig. 3.15 shows the flow cytometric analysis of one representative 
experiment from which it can be noticed that, although an increase in B cell proliferation 
occurred in the presence of both wt and baff-/- MCs, the frequency of proliferating CD19+ cells 
was slightly lower in the co-culture with BAFF-deficient MCs. Indeed, the 2.3% of dividing 
cells detected among B lymphocytes cultured alone, increased to 9.5% and 8.3% in the co-
culture with resting wt and BAFF-deficient MCs respectively. Similarly, in the case of 
IgE/Ag-stimulated MCs, the frequency of proliferating B cells was 11.1% with wt MCs and 
10.3% with baff-/- MCs. 
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Figure 3.15. BAFF contributes to MC-induced murine B cell proliferation. CFSE-labeled B cells were 
cultured for 72 h either alone or in the presence of wt or baff -/- MCs. Diminished CFSE intensity, indicative of 
proliferation, was detected in CD19+ B cells by flow cytometry. CFSE profiles of B cell proliferation in the 
different conditions are shown for one representative experiment, out of three. 
 
The results obtained in the murine system were further investigated by analyzing what 
happened when recombinant human TACI-Fc was added to the co-culture system made of 
CD19+CD21+IgM+ primary human B cells and LAD2 MCs. Human B cell proliferation was 
followed through the BrdU assay, in which only replicating cells incorporate this thymidine 
analog into nuclear DNA and are detected by flow cytometry. Interestingly, the binding of 
TACI-Fc to human BAFF on MCs caused a reduction of the percentage of CD19+BrdU+ cells 
from 5.4% to 3.1%. The observed result was exclusively due to the interference with the 
signaling pathway induced by MC-expressed BAFF as the same effect was not observed 
when TACI-Fc was added to the medium of B cells cultured alone (Fig. 3.16). All together, 
these data suggest that BAFF contributes to MC-driven sustainment of B lymphocytes. 
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Figure 3.16. BAFF contributes to MC-induced human B cell proliferation. Primary human B cells and LAD2 
MCs were cultured in a 1:1 ratio for 72 h, in the presence (B NST + LAD2 + TACI-Fc) or absence (B NST + 
LAD2) of human TACI-Fc (5µg/ml). The frequency of CD19+ cells that had synthesized DNA, and therefore 
incorporated BrdU, was determined by immunofluorescent staining with a FITC-conjugated anti-BrdU Ab and 
consequent flow cytometric analysis. As a control, the same experiment was performed also in B cells cultured 
alone (B NST). Dot plots for each condition are shown for one representative experiment, out of three. 
 
3.2.3. Modulation of BAFF-R and TACI expression by MCs 
 
Given the relevant contribution of MC-expressed BAFF to the sustainment of B lymphocytes, 
our next aim was to analyze BAFF receptor profile on murine B cells after co-culture with 
MCs. BAFF can bind to three receptors, BAFF-R, TACI and BCMA, each of which has a 
diverse specificity for the cytokine and a different expression pattern among all the B cell 
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subsets (Thompson et al., 2001). In particular, our interest was focused on BAFF-R and TACI 
since, historically, they are the best defined among the three BAFF receptors (Coquery and 
Erickson, 2012). 
To assess whether MCs could modulate the expression of BAFF-complementary surface 
molecules, freshly purified splenic B cells were cultured for 48 h with either unstimulated or 
IgE-Ag-stimulated MCs, in a 1:1 ratio. Consecutively, cell surface expression of TACI and 
BAFF-R was determined by flow cytometric analyses. Interestingly, a down-regulated 
expression of both receptors was observed on unstimulated B cells after co-culture with either 
non-sensitized or IgE-Ag-stimulated MCs (Fig. 3.17A, B). This observation can be explained 
as the result of an increased rate of BAFF-R and TACI internalization or as a down-
modulation of gene expression, both induced by BAFF-binding. However, more detailed 
studies are required to understand the exact mechanism at the basis of this result. Of note, the 
reduced levels of BAFF-R and TACI, detected following incubation with MCs, were not 
observed in the case of B cells activated with purified anti-mouse CD40 and anti-mouse IgM 
Ab (Fig. 3.17C, D), further supporting the hypothesis that MC-expressed BAFF is relevant in 
a condition of paucity of B cell survival and activating factors. 
 
                                                                                                                                Results and discussion 
 
 
 
Figure 3.17. Modulation of BAFF-R and TACI expression on B cell surface, after culture with MCs. (A, B) B 
cells were cultured either alone (B nst) or with MCs (B+MC; B+MC IgE/Ag) for 48 h. At the end of incubation, 
cells were collected and stained with anti-CD19 Ab and anti-BAFF-R or anti-TACI Ab. Histograms show either 
BAFF-R (A) or TACI (B) mean fluorescence intensity (MFI) in each condition. Reported results show means (± 
SEM) from five independent experiments. * p<0,05; *** p<0,001. (C, D) The same experiment was performed 
on B cells activated  with purified anti-mouse CD40Ab (1µg/ml) and anti-mouse IgM Ab (0.5µg/ml). Reported 
results show means (± SEM) from four independent experiments. * p<0,05. 
 
3.2.4. MC-expressed BAFF does not affect AID expression in B lymphocytes 
 
Along with the induction of B cell proliferation and survival, MCs were also shown to play a 
role in the induction of humoral immune responses since they provide important signals that 
switch Ab production and CSR (Merluzzi et al., 2014). Several reports have demonstrated that 
MCs support IgE synthesis by B cells through CD40L, IL-4 and IL-13 expression (Gauchat et 
al., 1993; Pawankar et al., 1997; Ryzhov et al., 2004). Moreover, IgE/Ag activated MCs were 
also proved to induce IgA surface expression and secretion in activated B cells (Merluzzi et 
al., 2010). The process of CSR, together with SHM, increases the diversity of Igs and requires 
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a fundamental enzyme, named AID, which is predominantly expressed in GC B cells (Park, 
2012). Among the classic factors known to induce AID expression in B lymphocytes (LPS, 
IL-4, CD40L), also BAFF and APRIL have been reported (Castigli et al., 2005; Kim et al., 
2011; Litinskiy et al., 2002). 
All together these evidences prompted us to investigate if MCs could induce AID expression 
in primary murine B cells and whether membrane-bound BAFF could constitute one of the 
factors through which MCs could exert this function. Since MCs could either induce the de 
novo synthesis of this enzyme or potentiate an AID-inducing biological context, their role was 
assessed both in the presence (anti-mouse CD40 Ab plus IL-4) and absence (unstimulated B 
cells or B cells activated with anti-mouse CD40 Ab plus anti-mouse IgM Ab) of AID-
inducing stimuli (Fig. 3.18A). In all cases, 5x106 B cells were cultured for 96 h either alone or 
in a 1:1 ratio with resting or IgE/Ag-activated MCs. AID transcripts were measured by qPCR 
in B cells cultured alone and in B cells which were separated from MCs through a immuno-
affinity system, based on the use of magnetic beads conjugated to the anti-CD45R/B220 Ab. 
Although the differences did not reach statistical significance due to the presence of high 
variability among the performed experiments, the results presented in Fig. 3.18B and 3.18C 
clearly show that IgE/Ag-stimulated MCs are able to promote AID expression both in 
unstimulated B cells and in B cells activated with anti CD40 and anti IgM Abs,. Conversely, 
when B cells were stimulated with IL-4, MCs did not increase the levels of AID mRNA 
expression (Fig. 3.18D), suggesting that MCs might provide fundamental signals for CSR and 
SHM in the lack of optimal AID-inducing stimulation. 
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Figure 3.18. Role of B cell activating stimuli and of MCs in the regulation of AID gene expression. (A) 5x106 
purified B cells were cultured at 106/ml in the absence of stimulation (NST) or in the presence of either agonistic 
CD40 mAb plus anti-IgM Ab or of agonistic CD40 mAb plus IL-4. Expression of AID was assessed by qPCR 
after 96 h from the beginning of stimulation. The expression levels are shown as fold induction over 
unstimulated B cells and the G3PDH transcript levels were used to normalize samples. Reported results show 
means (± SEM) from two experiments. (B, C, D) Unstimulated B cells (B) or B cells activated with either 
agonistic CD40 mAb plus anti-IgM Ab (C) or of agonistic CD40 mAb plus IL-4 (D) were cultured at 106/ml in 
the presence or absence of either resting or IgE/Ag-activated MCs. Prior to RNA extraction, MCs and B cells 
from the co-culture system were separated through a immuno-affinity system based on the use of magnetic beads 
conjugated to the anti-CD45R/B220 Ab. In all tested conditions, the expression levels are shown relative to the 
expression level in B cells cultured alone and G3PDH was used to normalize samples. Reported results show 
means (± SEM) from at least n=5 (B, D) and n=3 (C) independent experiments. 
 
Next, we used a TACI-Fc to test whether BAFF could contribute to MC-driven induction of 
AID expression. Since our results showed that the MC played a relevant role especially when 
B cells were activated through CD40 and BCR, the effect of TACI-Fc addition was evaluated 
in the co-culture between IgE/Ag-activated MCs and B cells stimulated with anti-CD40 Ab 
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plus anti-IgM Ab. As shown in Fig. 3.19, our results lead to the conclusion that MC-produced 
BAFF is not involved in AID induction since no reduction in AID mRNA expression was 
observed in the presence of TACI-Fc. 
 
 
Figure 3.19. MC-expressed BAFF does not contribute to AID induction in B cells activated through CD40 
and BCR. 5x106 purified B cells were incubated with anti-CD40 and anti-IgM Abs and cultured for 96 h in the 
presence or absence of IgE/Ag-activated MCs. The co-culture condition was also performed in the presence of a 
TACI-Fc. Expression of AID was assessed by qPCR. In all tested conditions the expression levels are shown 
relative to the expression level in B cells cultured alone. Reported results show means (± SEM) from at least 
three independent experiments. 
 
3.2.5. BAFF is not involved in MC-induced IL-10-competent B cell expansion 
 
In the last years, one of the most important topic discussed among immunologists is the 
capacity of the immune system to finely regulate, and not only activate, the immune response. 
Among the cells that play this important role, great interest has been recently devoted to 
regulatory B cells which were shown to suppress immune responses by means of the 
production of the anti-inflammatory cytokine IL-10 (Candando et al., 2014; Mauri, 2010). To 
date it has been widely demonstrate that stimulation through CD40 is essential for the 
induction of regulatory B cells even if other signaling pathways were proved to play a role. 
Among all, BAFF was shown to induce MZ B cell differentiation into IL-10-producing B 
cells and the in vivo transfer of BAFF-induced IL-10+ B cells significantly inhibited the 
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development of collagen-induced arthritis in mice (Yang et al., 2010a). Interestingly, it has 
been recently demonstrated that MCs control the expansion and differentiation of IL-10-
competent B cells, both in vitro and in vivo, and that the CD40L/CD40 axis plays a significant 
role in this important MC-function (Mion et al., 2014a). Thus, as a next step in our 
investigation of the functions of MC-expressed BAFF in the B/MC crosstalk, we decided to 
assess whether membrane-bound BAFF could also contribute to MC-driven expansion of IL-
10-competent B cells. 
Murine wt or baff -/- MCs were cultured together with splenic B cells at a 1:1 ratio for 48 h. 
5 h before cell harvesting, a mixture of LPS, PMA, ionomycin and monensin (LPIM) was 
added to the co-culture to induce cytoplasmic IL-10 production in IL-10-competent B cells 
and block protein secretion. As shown in Fig. 3.20, the production of BAFF by wt MCs does 
not play a significant role in their ability to induce IL-10-competent B cells since no 
difference was observed in the percentage of CD19+IL-10+ cells in respect to the baff -/- 
condition. A reduction of IL-10-competent B cells was neither observed when blocking BAFF 
signaling through the addition of murine TACI-Fc to the B/MC co-culture (data not shown). 
Therefore, this data lead to the conclusion that MC-expressed BAFF does not provide IL-10-
competent B cell differentiation signals. 
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Figure 3.20. MC-expressed BAFF does not contribute to MC-driven expansion of IL-10-competent B cells. 
IL-10-competent B cells were analyzed among B cells stimulated with anti-CD40 Ab (positive control) or 
cultured for 48 h with either wt or baff -/- MCs. In all conditions, LPIM was added for the last 5 h of culture. Dot 
plots for one representative experiment are shown. CD19 versus Live/Dead plots allow to identify viable B cells 
and exclude both MCs, which are negative for CD19 staining, and dead cells that are positive for Live/Dead 
staining. Only viable B cells were analyzed for IL-10 staining, and a perfectly matched isotype control was used 
to discriminate IL-10+ from IL-10- B cells (not shown). Bar graphs indicate mean (±SEM) percentages of IL-10+ 
cells among total B cells (n = 2). 
 
3.3. MC-DERIVED BAFF AND MULTIPLE MYELOMA 
 
3.3.1. MCs of MM patients present strong BAFF expression 
 
For a long time the study of BAFF has been almost exclusively related to the field of 
autoimmunity. However, the system made up of BAFF and its receptors is emerging as a 
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noteworthy component in several B-cell malignancies, where it has been shown to play a 
relevant role for the survival of the transformed B cell (Shivakumar and Ansell, 2006; 
Vincent et al., 2013). Depending on the specific B-cell neoplasia in analysis, BAFF can be 
expressed by tumor associated cells (paracrine signaling), by the malignant B cell itself 
(autocrine signaling) or by both these components of the tumor microenvironment. Stromal 
cell-production of BAFF was shown to play a key role in the support of mantle cell 
lymphoma (Medina et al., 2012), while malignant Hodgkin and Reed-Sternberg cells receive 
survival and proliferation signals from the binding of BAFF produced by both the malignant 
cells and by the reactive myeloid cells infiltrating the tumor (Chiu et al., 2007). 
In light of all these evidences, we decided to further corroborate our in vitro findings 
relatively to BAFF production by MCs, by analyzing the in vivo context of a B-cell neoplasia. 
Among all, we decided to focus on MM, since a relevant role in the pathophysiology and 
progression of this disease has been described for both MCs (Ria et al., 2011; Ribatti et al., 
1999, 2004) and BAFF (Fragioudaki et al., 2012; Moreaux et al., 2004). With this aim, and in 
collaboration with the group of Professor Vacca at the University of Bari, we analyzed the 
expression of BAFF on MCs through confocal microscopy and immunohistochemistry 
analysis of bone marrow biopsies of healthy controls and of MGUS and MM patients. As 
shown in panel A of Fig. 3.21, among the rare MCs found in the bone marrow sections of 
healthy controls, none was found to be positively stained for BAFF. Conversely, tryptase-
positive BAFF-producing cells were detected in sample of MGUS patients (Fig. 3.21B) and, 
to a greater extent in MM patients (Fig. 3.21C). 
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Figure 3.21. BAFF expression by MCs of healthy, MGUS and MM bone marrow biopsies. 
Immunohistochemistry (top panels) and immunofluorescence (bottom panels) for MC tryptase (brown in IHC; 
red in IF), BAFF (pink in IHC; green in IF) and nuclei (blue) on bone marrow biopsies from healthy subjects 
(A) and from patients with MGUS (B) or MM (C). Data are representative of bone marrow biopsies from three 
different healthy subjects, MGUS and MM patients. Original magnification and scale bars respectively = x100, 
20µm. 
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The immunohistochemical images at higher magnification shown in Fig. 3.22 allow to better 
appreciate the correlation between the number of MCs, the degree of BAFF staining and the 
progression of the disease. Indeed, though it needs to be underlined that a certain degree of 
variability is present among both healthy subjects and patients, the representative images 
clearly show how a higher number of BAFF+ MCs can be found in bone marrow biopsies of 
MM patients compared to healthy and MGUS conditions. 
 
Figure 3.22. Correlation between BAFF-positive MCs and the progression of the disease. Representative 
tryptase (brown, MCs) and BAFF (pink) staining of sections from bone marrow biopsies of healthy controls and 
of MGUS and MM patients. Arrows indicate BAFF-positive MCs. Original magnification: 40X. Scale bar: 50 
µm. 
 
All together, these analyses indicate that MCs can produce BAFF in vivo, and that the 
expression of this cytokine might be influenced by the tumor microenvironment. Moreover, 
given the importance of BAFF in B-cell survival, these results suggest that the role of the MC 
in MM might go beyond the promotion of bone marrow angiogenesis and could be extended 
to a contribution in the maintenance and/or growth of the malignant B-cell clone, which 
would obviously lead to the exacerbation of the disease. 
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3.3.2. BAFF expression is up-regulated by the conditioned medium of myeloma 
cells 
 
In the context of MM, it has been shown the existence of an autocrine survival loop in which 
myeloma cells themselves produce BAFF and APRIL to support their growth and survival 
(Moreaux et al., 2004). The observed correlation between the number of BAFF-positive MCs 
and the progression of the disease, lead us to investigate whether signals released by myeloma 
cells could modulate BAFF expression on MCs. 
Given the technical difficulties at the base of cell isolation from bone marrow aspirates, the 
human MM cell line RPMI 8226 was employed to this end. RPMI 8226 cells were first 
checked for the expression of both the CD38 and CD138 cell surface markers (Fig. 3.23A), 
which characterize the phenotypic profile of primary myeloma cells (Paíno et al., 2014). 
Myeloma cells were then cultured for 48 h and cell supernatant was collected and used, in 
three different proportions (pure or diluted 1:2 or 1:4 in standard culture medium) to stimulate 
HMC-1.2 cells. After 24 h of culture, HMC-1.2 cells were collected and assessed for the 
expression of membrane-bound BAFF by flow cytometry. Interestingly, when human MCs 
were cultured with pure conditioned media from RPMI 8226 cells, a significant reduction of 
BAFF expression was observed relative to HMC-1.2 cells grown in standard culture medium 
(Fig. 3.23B). 
The obtained result suggests that soluble mediators released by RPMI 8226 cells can up-
regulate the expression of the membrane-bound form of BAFF in human MCs. At this point, 
the next step would have been to assess which of the various factors produced by myeloma 
cells could be responsible for this effect. However, given that these factors are numerous and 
different, this step requires a careful analysis of the literature in order to identify the best 
candidate, and it therefore represents one of the future goals of this project. 
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Figure 3.23. Membrane-bound BAFF expression on HMC-1.2 is affected by soluble mediators released by 
RPMI 8226 cells. (A) Histogram and dot plots showing the expression of CD38 and CD138 on RPMI 8226 cells. 
(B) HMC-1.2 cells were cultured for 24 h with standard culture medium (medium) or in the presence of 
conditioned medium (CM) of RMI8226 cells which was used pure (100% CM RPMI) or diluted 1:2 (50% CM 
RPMI) or 1:4 with standard culture medium (25% CM RPMI). At the end of incubation, membrane-bound BAFF 
expression was assessed on HMC-1.2 cells by flow cytometry. Histogram graph show the mean fluorescence 
intensity (MFI) of BAFF for each condition. Reported results show means (± SEM) from three independent 
experiments. * p<0,05. 
 
3.3.3. Role of MC-derived BAFF in myeloma cell survival 
 
The evidence that BAFF-positive MCs are present in bone marrow biopsies of MM patients 
together with our finding that MC-expressed BAFF contributes to MC-driven survival of 
normal B cells, lead us to assess whether an uncontrolled version of this mechanism could 
contribute to the maintenance of the malignant B cell clone, thus exacerbating or sustaining 
the disease. 
With this aim, we set up a culture system in which RPMI 8226 myeloma cells were seeded 
alone or with HMC-1.2 cells and cultured in the presence or absence of the soluble TACI-Fc 
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decoy receptor. 48 h later, the viability of RPMI 8226 cells was assessed in the different 
conditions. It must be kept in mind that, as already reported by Moreaux and coworkers 
(Moreaux et al., 2004), TACI-Fc blocks the autonomous growth of RPMI 8226 cells (Fig. 
3.24A), complicating the investigation of the role of BAFF and APRIL in the co-culture 
system made of the two cell lines. As shown in panel B of Fig. 3.24, in our preliminary 
results, the effect of the addition of TACI-Fc is almost the same in the conditions in which 
RPMI cells are cultured alone or with HMC-1.2, even if a slight difference is observed among 
viable cells. An improved tuning of the experimental set-up together with a greater number of 
experiments are required in order to better define the role of MCs in the maintenance of the 
malignant B cell clone in MM. 
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Figure 3.24.Role of BAFF in the growth and survival of RPMI 8226 grown alone or with HMC-1.2 cells. (A) 
Cell viability measured with MTT assay (fold absorbance compared to RPMI 8226 untreated cells). RPMI 8226 
were cultured for 72 h with medium and with medium plus TACI-Fc. (B) The percentage of viable and necrotic 
RPMI 8226 cells was analyzed through Annexin V/Propidium Iodide assay after 48 h of culture with or without 
HMC-1.2 cells and in the presence (+TACI-Fc) or absence (medium) of the human TACI-Fc decoy receptor. 
Staining with anti-CD38 Ab was necessary to distinguish RPMI 8226 from HMC-1.2 cells. Results are shown as 
fold induction over the “medium” condition and are the means of two independent experiments. 
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4. CONCLUSIONS 
 
The immune system is composed of multiple cell types, which together improve the resistance 
of the organism against infections. The unfolding of a successful host response ensuring 
effective protection against pathogens requires an appropriate coordination of the different 
players of the immune system. In this context, MCs are well placed in a strategic location at 
the host-environment interface, where they serve as immune sentinel cells that respond 
directly to pathogens and send signals to other tissues to modulate both the innate and 
adaptive immune response. Indeed, MCs can be detected in serosal cavities and immediately 
beneath epithelial surfaces, as well as near blood vessels. This peculiar MC-function is due to 
the expression of an array of adhesion and immune receptors that may assist in the 
recognition of invading pathogens and in the sampling and integration of different stimuli 
(Frossi et al., 2004; Metz et al., 2008). Interestingly, in the last few years it has been shown 
that MCs can exert an homeostatic role on the control of the development, tissue homing and 
activation of immune and non-immune cell populations independently from the infectious 
stimuli or MC activation too. Activation and/or suppression of innate and adaptive immune 
cells depend on cell-cell interactions and on the cytokines released by MCs (Gri et al., 2012). 
The present thesis involves studies on the crosstalk between MCs and B cells and describes 
the contribution of MC-produced BAFF on this axis. In the laboratory in which this work of 
thesis was performed, it was demonstrated that resting MCs (and to lesser extent the activated 
MCs too) deliver helper signals to B cells via both direct and indirect mechanisms. In fact, 
MCs promote both survival and activation of naive B cells as well as proliferation and further 
plasma cell differentiation of activated B cells through cell-cell contact and the production of 
soluble factors (Merluzzi et al., 2010; Mion et al., 2014a). In our effort to define soluble and 
membrane-bound molecules involved in this process, we found that a fundamental role is 
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played by the CD40:CD40L axis and by IL-6. However, different signals are able to sustain 
the B cell proliferation and differentiation in a TI manner. In fact, TI Ab responses usually 
unfold at the mucosal interface or in the splenic MZ and generate polyspecific and low-
affinity Abs through a TI pathway involving the interaction of B cells with DCs, 
macrophages, and granulocytes (Puga et al., 2012). These innate immune cells deliver Ab-
inducing signals via BAFF and APRIL (He et al., 2010; Puga et al., 2012). However, 
considering the role of MC in TI B cell activation, we studied if BAFF could be a cytokine 
involved in the MC/B cell axis. 
We found that the murine MC line MC/9, BMMC and the human MC lines HMC-1.2 and 
LAD2 constitutively expressed BAFF mRNA, even if at lower levels than in the positive 
controls, the macrophage-like murine RAW 264.7 and human U937. Moreover, BAFF protein 
was detected bound at cell membrane, and in cytoplasmic stores, but was not released under 
the investigated conditions. Additionally, IgE/Ag-, IFN-γ-, and LPS-activated MCs do not 
show a modulation of BAFF gene expression, both in the murine and human system. It has 
been shown that in vivo there is a complex regulation of the stored, membrane-bound and 
released form of BAFF which could, probably, not be reproduced in our in vitro conditions. 
Innate immune cells, DCs, macrophages and granulocytes, deliver Ab-inducing signals via the 
CD40L-like cytokine BAFF, and can also potentiate BAFF activity to deliver TI signals 
through other members of the same family, such as APRIL (Mackay et al., 2007a). In this 
light, we also analyzed APRIL gene expression in murine MCs. Surprisingly, we found that 
both LPS-activated BMMCs and MC/9 showed a decreased APRIL mRNA expression but an 
increase of the same cytokine mRNA was detected in IgE/Ag-stimulated MC/9. 
Moving to the protein level, it is worth to note that the analysis of BAFF protein is 
influenced by the detection system and by the anti-BAFF Abs used in the assay. Indeed, 
Schneider and co-workers, in a comment to Chu et al paper (Chu et al., 2009), which 
described the aberrant production of BAFF by over-activated B cells in patients with SLE, 
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underlined that the work overestimated the quantity of BAFF and this was dependent on the 
used mAb and recognized BAFF epitopes (Schneider and Huard, 2010). Taking advantage of 
these studies, we investigated BAFF expression using multiple complementary techniques. 
We found membrane-bound BAFF expression by murine and human cells using 
cytofluorimetric analysis. Additionally, confocal experiments confirmed that BAFF protein is 
expressed on MC-membrane, but is stored intracellularly too. For long time, soluble BAFF 
has been considered the predominant form of the cytokine but recently, it has been shown that 
a non-cleavable membrane-bound form of BAFF was at least 50-fold more active than soluble 
BAFF at delivering signals to responder cells (Bossen et al., 2008). This data has been 
recently stressed by Kikly’s group (Manetta et al., 2014) and suggests that BAFF behave like 
a co-stimulatory molecule which contributes to the interaction between different immune 
cells, leading to strong signals of survival and proliferation. Newsworthy, in our analysis of 
membrane-bound BAFF among different MC cultures, we noticed that, similarly to CD40L 
(Merluzzi et al., 2014), the expression of BAFF differs with the differentiation stage and 
culture age of MC, heterogeneity of precursors etc. This underlines the complexity of the 
BAFF system and the fine modulation that could be dependent on functional requests coming 
from the microenvironment, elaborated by MCs and transduced to the adaptive immunite 
system through the modulation of co-stimulatory molecules. In our system we were not able 
to detect BAFF in the supernatant of both human and murine MCs. We will investigate 
whether MCs have the ability to cleave the membrane-bound form of BAFF or if the 
expression of exclusively mBAFF is a peculiairity of MCs and of the MC/B cell crosstalk. 
In order to understand the role of mBAFF in the MC/B cell interaction, we have first 
investigated, both in murine and human models, the survival of B cells co-cultured with MCs 
using a TACI-Fc molecule to block BAFF activity. We have demonstrated that BAFF 
antagonist induce a reduction of viable B cells, highlighting the role of this cytokine as a 
survival factor. However, it is important to note that human MCs express the membrane-
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bound form of APRIL and the TACI-Fc functionally blocks APRIL activity too (Ho et al., 
2008). In the next future, it is our aim to investigate the different contribution of APRIL and 
BAFF in MC/B cell interaction. However, in the murine system, the obtained results were 
validated using MCs differentiated from the bone marrow of baff -/- mice.. 
BAFF plays a critical role in B cell survival and immune responses by binding to one of its 
three receptors: BAFF-R, TACI and BCMA (Zhang et al., 2005b). Using specific Abs, we 
have investigated the expression of BAFF-R and TACI on the surface of B cells co-cultured 
with MCs and we observed that there is a decrease of their expression on resting B cells. 
Interestingly, the reduced levels of BAFF-R and TACI were not observed in the case of B 
cells activated with anti-mouse CD40 mAb plus anti-mouse IgM Ab. This can support the 
hypothesis that MC-expressed BAFF is relevant in a condition of poorness of B cell survival 
and activating factors. 
Since that our laboratory has been demonstrated that MC enhance B cells proliferation, 
leads B cells survival and drive their differentiation towards IgA secreting plasma cells 
(Merluzzi et al., 2010), in order to understand if BAFF on MCs plays a role in the induction 
of IgA switching on B cells, we have investigated if in B cells cultured with MCs there is an 
increase of AID expression. We have found that MCs induce AID transcription both in resting 
B cells and in B cells activated with anti-mouse CD40 mAb plus anti-mouse IgM Ab. 
However, baff -/- MCs did not affect this induction. 
To assess whether the MC affect the activity of all B cells or of a peculiar subpopulation, 
we also analyzed the effect of BAFF on MC-driven expansion of IL-10-competent B cells 
(Mion et al., 2014a), but our results did not show a significant effect. Indeed, the percentage 
of CD19+IL-10+ cells detected in the MC/B cell co-culture system did not change in the 
presence or absence of MC-produced BAFF. 
Beside its role in the physiological context, BAFF protects myeloma cells from apoptosis 
and sustain the survival of neoplastic B cells through the interaction with its three receptors 
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expressed on myeloma cell surface (Sun et al., 2008). In collaboration with Professor A. 
Vacca at University of Bari, we have analyzed MM sections and we found BAFF+ MCs 
infiltrating the bone marrow. The number of MCs positively stained for mBAFF was 
decreased in bone marrows derived by MGUS patients and no MCs were detected in those of 
healthy controls. For the first time, we have found that MCs can be the source of mBAFF in 
the bone marrow of MM patients and probably contribute to the survival of neoplastic B cells 
in the bone marrow niches. In in vitro experiments using the conditioned media of the human 
myeloma cell line RPMI 8226 we found that the HMC-1.2 human MC line upregulated 
mBAFF expression. These preliminary results indicate a positive loop between MCs and 
myeloma cells in which soluble factors from myeloma cells induce BAFF expression on MCs. 
The expressed cytokine could than contribute to the formation of a favoring 
microenvironment for myeloma cells. Further investigations will help to define molecular 
targets that can be used to disrupt this important survival axis in MM.
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5. MATERIALS AND METHODS 
 
5.1. Solutions and culture media 
 
• Culture medium for BMMCs 
RPMI 1640 (Euroclone) 
20% FBS (Fetal Bovine Serum) (Sigma Aldrich) 
20 mM Hepes (Euroclone) 
2 mM L-glutamine (Euroclone) 
1 mM sodium pyruvate (Euroclone) 
1X non-essential amino acids (from 100X mix, Euroclone) 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Euroclone) 
50 mM β-mercaptoethanol (Sigma Aldrich) 
20 ng/ml IL-3 (PeproTech)  
20 ng/ml SCF (PeproTech) 
• Culture medium for B cells and MC/B cell co-cultures 
RPMI 1640 (Euroclone)  
10% FBS (Sigma Aldrich) 
20 mM Hepes (Euroclone) 
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2 mM L-glutamine (Euroclone) 
1 mM sodium pyruvate (Euroclone) 
1X non-essential amino acids (from 100X mix, Euroclone) 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Euroclone) 
50 mM β-mercaptoethanol (Sigma Aldrich) 
• Culture medium for the cell lines HMC-1.2, U937, A20 
RPMI 1640 (Euroclone)  
10% FBS (Sigma Aldrich) 
20 mM Hepes (Euroclone) 
2 mM L-glutamine (Euroclone) 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Euroclone) 
• Culture medium for the murine cell line MC/9 
Dulbecco’s modified Eagle’s medium: DMEM (Euroclone)  
         10 % FBS (Sigma Aldrich) 
2 mM L-glutamine (Euroclone) 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Euroclone) 
20 mM Hepes (Euroclone) 
2 mM L-glutamine (Euroclone) 
1 mM sodium pyruvate (Euroclone) 
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1X non-essential amino acids (from 100X mix, Euroclone) 
20 ng/ml IL-3 (PeproTech) 
• Culture medium for the human cell line LAD2 
StemPro-34 (Invitrogen, Carlsbad, CA) 
2mM glutamine (Euroclone) 
100 ng/ml human SCF (Peprotech)   
• Culture medium for the cell lines RAW 264.7 and HEK 293 
         Dulbecco’s modified Eagle’s medium: DMEM (Euroclone)  
10% FBS (Sigma Aldrich) 
2 mM L-glutamine (Euroclone) 
antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin) (Euroclone) 
• Phosphate Buffered Saline (PBS) 
137 mM NaCl (Sigma Aldrich) 
27 mM KCl (Sigma Aldrich) 
4.3 mM Na2HPO4 (Sigma Aldrich) 
1.4 mM KH2PO4 (Sigma Aldrich) 
pH 7.4 
• Tyrode’s buffer  
     135 mM NaCl (Sigma Aldrich) 
     5 mM KCl (Sigma Aldrich) 
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     1 mM MgCl2 (Sigma Aldrich) 
     1.8 mM CaCl2 (Sigma Aldrich) 
     5.6 mM Glucose (Sigma Aldrich) 
     20 mM Hepes (pH 7,4) (Sigma Aldrich) 
• MIN buffer  
PBS pH 7.4 
2 mM EDTA (Sigma Aldrich)  
0.5% BSA (Sigma Aldrich) 
• TAE buffer (10x) 
48.5 g Tris2 mM EDTA (Sigma Aldrich) 
         11.4 mL glacial acetic acid (Sigma Aldrich) 
         20 mL 0.5M EDTA (pH 8.0) (Sigma Aldrich) 
• STAINING BUFFER 
DPBS 1X 
      Sodio azide 0,09% (Sigma Aldrich) 
      FBS 3% (Sigma Aldrich) 
        
5.2. Mice and cell lines 
 
Female C57BL/6 (B6) mice (Harlan Laboratories) were used for all the experiments 
performed in this thesis. Femurs of BAFF-deficient (baff -/-) mice were kindly provided by 
Prof. P. Schneider from the Department of Biochemistry, University of Lausanne, Epalinges, 
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Switzerland. The MC/9 cell line is a cloned MC line derived from the fetal liver of a B6 X A/J 
F1 mouse. The human MC line HMC-1.2 was kindly provided by Prof. J. Rivera’s laboratory. 
This cells are a factor-independent, fast growing, immature MC line derived from the 
peripheral blood of a patient suffering from MC leukemia. The human LAD2 MC line was 
kindly provided by A. Kirshenbaum (NIH, Bethesda, MD). This cell line was established 
from bone marrow aspirates of a patient with MC sarcoma leukemia and is closely related to 
human MCs. RAW 264.7 is a murine macrophage cell line. U937 cells are human monocytes 
derived from hystocytic lymphoma. HEK-293 are adherent embryonic kidney cells. RPMI 
8226 cells are B lymphocytes derived from a myeloma, kindly provided by professor A. 
Vacca (Univerisity of Bari). C2C12 cells were a subclone (produced by H. Blau, et al) of the 
C2 mouse myoblast cell line established by D. Yaffe and O. Saxel. The A20 cell line is a 
BALB/c B cell lymphoma line derived from a reticulum cell sarcoma. 
 
5.3. BMMCs differentiation and activation 
 
BMMCs were obtained by in vitro differentiation from wt and baff -/- mice. Murine MCs 
differentiated from bone marrow precursor cells are a useful tool to study the biological 
functions of these cells ex vivo. Bone marrow cells were isolated from the femurs of 5-6-
week-old mice: the bones were dissected using scissors, cutting through the tibia below the 
knee joints, as well as through the pelvic bone close to the hip joint. The epiphysis was 
removed from femur and wash medium was injected in the cavity using a syringe (BD 
Plastipak) with a 30 gauge needle (Microlance). Cellular suspension was collected in a tube 
(Sarsted), centrifugated and resuspended in culture medium for BMMCs (see 5.1) which 
contains IL-3 and SCF that are specific factors for the differentiation of MCs. The maturation 
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of BMMCs was monitored assessing c-Kit and FcεRI expression by flow cytometry after 4-5 
weeks. BMMCs were used when purity was more than 90-95%. 
 
 
Figure 5.1 . Purity of the bone marrow-derived MC population. Representative example of FACS analysis to 
evaluate BMMC maturation. Mature BMMCs, gated on the basis of their size and granularity (FSC vs SSC plot, 
left side), are positively stained for both FcεRI and c-Kit (right panel). 
  
For IgE-dependent stimulation, BMMCs were sensitized with 1 µg/ml of dinitrophenol 
(DNP)-specific IgE in medium without IL-3 for 3 h and then eventually treated with IgE 
specific Ag DNP (Sigma-Aldrich). Alternatively, MCs were activated in an IgE-independent 
manner, with IFN-γ (40 ng/ml) or LPS (1 µg/ml), which are other classical stimuli for MC-
activation. 
 
5.4. Activation of the human MC lines HMC-1.2 and LAD2 
 
Human cell lines were cultured in the appropriate media (as described in paragraph 5.1) and 
stimulated for 5 h. HMC-1.2 cells were stimulated with LPS (1 µg/ml) and with IFN-γ (8 
ng/ml). LAD2 were stimulated with LPS (1 µg/ml) or overnight pre-sensitized with 1 µg/ml 
of human myeloma IgE and then stimulated with 15 µg/ml of anti-human IgE (Sigma-
Aldrich).   
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5.5. β-hexosaminidase release assay   
 
IgE-pre-sensitized BMMCs were challenged in Tyrode’s buffer with DNP Ag (50 ng/ml) for 
30 minutes. At the end of incubation, samples were placed on ice for 5 minutes and 
immediately centrifuged. The enzymatic activities of β-hexosaminidase in supernatants and in 
the cell pellets, after solubilization with 0.5% Triton X-100 in Tyrode’s buffer, were 
measured with p-nitrophenyl N-acetyl-b-D-glucosaminide in 0.1 M sodium citrate (pH 4.5) 
for 60 minutes at 37°C. The release of the product 4-p-nitrophenol was detected by 
absorbance at 405 nm after addition of carbonate/bicarbonate tampon. The extent of 
degranulation was calculated as the percentage of 4-p-nitrophenol absorbance in the 
supernatants over the sum of absorbance and in cell pellets solubilized in detergent. 
  
5.6. Total RNA isolation, RT-PCR and qPCR 
 
Total RNA was extracted from 5x106 cells (either murine MCs, human MCs or B 
lymphocytes) using TRIzol (Invitrogent) or Riboex (GeneAll) reagent and according to the 
manufacturer’s instructions. The extracted RNA was quantified using a spectrophotometer 
and by measuring the optical density at 260 nm. Its quality was checked by measuring the 
OD260/OD280 ratio. RNA (1 µg) was reverse transcribed to cDNA using the iScript cDNA 
Synthesis kit (Biorad) or the FirstStrand cDNA Synthesis Kit (Termo Scientific), according to 
manufacturer’s instructions. cDNA generated was amplified by reverse transcriptase 
polymerase chain reaction (RT-PCR) and/or by a quantitative real time PCR (qPCR), 
performed with a BioRad CFX device, using iQTM SYBR Green Super Mix (Biorad). cDNA 
was amplified by PCR reaction with a mix contains (for samples): 2.5µl Buffer 10X RedTaq 
(Sigma), 0.5 µl dNTPs mix (10mM), 0.9 µl MgCl2 25mM, 0.25 µl primer FOR (20 pmol/µl), 
0.25 µl primer REV (20 pmol/µl), 1 µl Enzyme RedTaq (Sigma), 5µl cDNA. PCR was 
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performed with the following parameters: 94°C for 5 minutes, 40 cycles at (94°C for 45 sec; 
59° C for 45 sec; 72°C for 60 sec) then 72 °C for 10 minutes. cDNA from each reaction was 
analyzed on a 2% agarose/EtBr gel, ran in 1X TAE buffer. Gel was analyzed with GelDoc 
(Biorad). Real Time PCR amplification were performed with the following parameters: 95°C 
for 3 minutes, followed by 39 cycles (95°C for 10 sec, temperature specific for each primer 
for 60 sec, for human and mouse BAFF, 30 sec for murine AID and APRIL). Specific 
temperatures were: mBAFF 64,5 °C, hBAFF 63,3 °C, mAID 58,9 °C. Specificity of the RT-
PCR products was assessed by the generation of a melting curve. Data from the reaction, each 
performed in triplicate, were collected and analyzed by the complementary computer 
software. Results were expressed as fold induction compared to control condition. G3PDH 
(mouse) and GAPDH (human) transcripts levels were used as normalizer for samples. Length 
of segments are the following: mBAFF 169 bp, hBAFF 368 bp, mAID 106 bp, mG3PDH 115 
bp, hGAPDH 452 bp. Primer used are the following: murine BAFF Forward: 
GACGCGCTTTCCAGGGACCAG Reverse: GTCGGCGTGTCGCTGTTCTGC murine 
AID Forward: AAGTCACGCTGGAGACCGAT Reverse: AGGTAGGTCTCATGCCGTCC  
APRIL Forward: ATGGGTCAGGTGGTGTCTCG Reverse: 
TCCCCTTGGTGTAAATGGAAGA murine G3PDH Forward: 
TCAACAGCAACTCCCACTCTTCCA Reverse: ACCCTGTTGCTGTAGCCGTATTCA 
human BAFF Forward: CAGCTCCAGGAGAAGGCAACT Reverse: 
CAATGCCAGCTGAATAGCAGG human GAPDH Forward: 
ACCACAGTCCATGCCATC Reverse: TCCACCACCCTGTTGCTG .  
 
5.7. Purification of mouse B cells  
 
Purified splenic B cells were obtained from 6-12-week-old mice by a negative depletion 
method that removes all undesired cells without manipulating the B cells themselves. Briefly, 
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spleens were removed and dissociated in PBS supplemented with 0.0192 M sodium citrate. 
Splenocyte cell suspension was depleted of red blood cells (RBCs) by hypotonic lysis with 
ACK lysing buffer (Sigma Aldrich) and of T cells by complement-mediated cytotoxic lysis 
using an anti-Thy 1.2 monoclonal Ab (a gift from K. Hathcock, Experimental Immunology 
Branch, NIC/NIH, Bethesda, MD USA) in conjunction with rabbit complement (Low-Tox M; 
Cedar Lane). The cell suspension was then cultured for at least one hour at 37°C and 5% CO2 
to allow the adhesion of mononuclear cells at the bottom of the flask. At the end of 
incubation, the cells in suspension were collected, washed and resuspended at a final 
concentration of 106 cell/ml in culture medium for B cells. To test the purity of the isolated B 
cells, a small aliquot of cells was checked by cytofluorimetric analysis for the expression of 
CD19; the percentage of CD19+ cells varied between 85 and 95% (Fig. 5.2). 
 
 
Figure 5.2 . Purity of the B cell population isolated from mouse spleen. In the scatter plot of forward scatter 
(FSC) vs side scatter (SSC) the cells are distributed based on their size and granularity. The lymphocytes (gated) 
form a tight population, clearly distinguishable from dead cells (on the left of the gated region) and from 
granulocytes (above the gated region). The hystograms reported in the picture show how the majority of the 
isolated lymphocytes (87.9%) are B cells and that the contamination from T cells accounts for only the 5.6% of 
total cells. 
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5.8.  Purification of human B cells 
 
For the purification of human B cells we followed the protocol of “RosetteSep Human B cell 
enrichment cocktail” kit (STEMCELL Technologies). This kit is designed to isolate B cells 
from whole blood by negative selection. The buffy coat of male healthy donors was provided 
by the “Azienda Ospedaliera Universitaria Santa Maria della Misericordia” of Udine. About 
40 ml of buffy coat was incubated with RosetteSep human B cell enrichment cocktail (50 
µl/ml). The RosetteSep Abs cocktail crosslinks unwanted cells in human whole blood to 
multiple RBCs, forming immunorosettes. This increases the density of the unwanted 
(rosetted) cells, such that they pellet along with the free RBCs when centrifuged over a 
buoyant density medium such as Ficoll-Paque PLUS. Desired cells are never labeled with Ab 
and are easily collected as a highly enriched population at the interface between the plasma 
and the buoyant density medium. After 20 minutes of incubation at room temperature, the 
sample was diluted with an equal volume of PBS plus 2% FBS and mixed gently. Then cells 
were further purified by separation in a Fycoll Paque Plus (GE Healthcare) density gradient 
and washed with PBS supplemented with 2% FBS. Human B cells were stained with human 
CD19 and then analyzed with FACS Calibur (Becton Dickinson) to ascertain the purity of the 
obtained cells. The cells were counted with Trypan Blue and resuspended in culture media 
RPMI (see 5.1) to be immediately used or frozen at -80 °C. 
 
5.9. B/LAD2 co-culture and BrdU assay 
 
B and LAD cells were cultured in a 96-well plate (ratio 1:1) in 200 µl of StemPro (Gibco) 
medium (see 5.1). After 48 h of co-culture, 10 µM of Bromodeoxyuridine (BrdU, Sigma) 
were added in each well to proceed, 24h later, to BrdU assay detection. BrdU is a common 
reagent used for cell proliferation assays and for the detection of apoptotic cells. BrdU is a 
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uridine derivative and a structural analog of thymidine, and it can be incorporated into DNA 
during the synthesis-phase of the cell cycle as a substitute for thymidine, thereby serving as a 
marker for proliferation. Cells which have incorporated BrdU may be detected by multiple 
detection methods using fluorescently-labeled or enzyme-linked anti-BrdU Abs. Cells were 
collected and stained for CD19, to discriminate the B population. After staining, cells were 
washed with staining buffer, centrifuged and then resuspended in 200 µl of Foxp3 
Fixation/Permeabilization buffer (eBioscience) for 30 minutes at 4 °C. After washing, the 
cells were incubated with 100 µl Dnase I (30µg/sample) to quantitatively expose BrdU-
labeled epitopes in cell suspension. Cells were incubated for 1 h at 4 °C. Finally, cells were 
labeled with anti-BrdU FITC (eBioscience) (1:80) for about 40 minutes and analyzed with 
citofluorimeter (Becton Dickinson FACScan). 
To evaluate the role of BAFF signaling pathway, the recombinant human TACI-Fc chimera 
(R&D) was added to the culture medium at the final concentration of 5 µg/ml and maintained 
for all the 48 h of culture.  
 
5.10. CFSE staining of cell division  
 
In order to study lymphocyte proliferation, cells were stained with carboxyfluorescein 
diacetate succinimidyl ester (CFDA-SE) (Molecular Probes, Invitrogen). CFDA-SE diffuses 
into cells where the acetate groups on the molecule are cleaved to yield a highly fluorescent 
derivative (CFSE) that is retained in the cell and can be detected by flow cytometry. Cell 
division results in sequential halving of fluorescence and up to eight cell divisions can be 
monitored before the fluorescence is decreased to the background fluorescence of un-
stimulated cells (Parish et al., 2009). 
Briefly, 107 B lymphocytes were washed and resuspended in 1 ml of complete culture 
medium for splenocytes. CFDA-SE was then added to a final concentration of 5 µM and 
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incubated for 15 minutes at 37°C, in the dark. The reaction was blocked by adding 1 ml of 
cold FBS and cells were then centrifuged (300 g for 5 minutes) and washed two times with 
wash medium. Finally, B cells were resuspended at the final concentration of 5x105 cell/ml in 
complete culture medium. 
 
5.11. Cytokine ELISA assay  
 
The test is a ‘’sandwich ELISA’’: the plate is coated with the capture Ab that recognizes the 
protein of interest (murine or human BAFF) in the samples. For the detection of the protein a 
second byotinilated Ab is used, that recognizes another epitope. Streptavidin-HRP and its 
substrate lead to a chromogenic reaction that allows the quantification of the protein present 
in the sample. Supernatants from different experimental settings were collected at the 
indicated times for quantification of murine (Boster Immunoleader) and human BAFF 
(R&D), through ELISA, according to manufacturer’s protocols.  
 
5.12. Co-culture of B lymphocyte with MCs 
 
For flow citometry experiments, B cells were co-cultured with MCs. 0.6x106 B cells were 
added to an equal number of IgE-sensitized or non-sensitized MCs, in the presence or absence 
of DNP, and cultured for 48 hours in a 24-well flat bottom plate (Corning Costar), in a final 
volume of 600 µl. To evaluate the role of BAFF signaling pathway in the B lymphocyte-MC 
co-culture, the recombinant murine TACI-Fc chimera (R&D) was added to the culture 
medium at the final concentration of 1 µg/ml and maintained for all the 48 h of culture. 
Otherwise B cells were cultured with MCs from baff -/- mice.  
                                                                                                                               Materials and Methods 
 
 
For RNA extraction, to measure AID gene expression in B cells, 4x106 purified mouse B cells 
were cultured in flask of 25 cm2, at the final concentration of 1x106 cells/ml. B cells were 
cultured alone unstimulated, stimulated with anti-CD40 mAb (1 µg/ml) and anti-IgM mAb 
(0,5 µg/ml) or with anti-CD40 mAb (1 µg/ml) and IL-4 (50 ng/ml) or with MC (ratio 1:1) 
unstimulated or IgE/Ag-stimulated (see 5.3). Moreover to evaluate the role of BAFF 
signaling, the recombinant murine TACI-Fc chimera (R&D) was added to the culture medium 
at the final concentration of 1 µg/ml. AID expression was evaluated in RNA extracted from B 
cells (see 5.9) that were cultured for 96 h. AID transcripts were measured by qPCR in B cells 
cultured alone and in B cells which were separated from MCs through a immuno-affinity 
system, based on the use of magnetic beads conjugated to the anti-CD45R/B220 Ab (MACS 
Miltenyi Biotec). MS columns (MACS Miltenyi Biotec) were used according to protocol. To 
test the purity of the separated B cells, a small aliquot of cells was checked by 
cytofluorimetric analysis for the expression of CD19 (Fig. 5.3 ).  
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Figure 5.3. Purity of post sorter B cells. In the scatter plot of forward scatter (FSC) vs side scatter (SSC) the 
cells are distributed based on their size and granularity. The lymphocytes form a tight population, clearly 
distinguishable from dead cells (on the left of the gated region) and from MCs (above the gated region).The 
graphs on the right reported CD19/cKit stained cell. In the sample of cells post sorter, B cells represents 93.2 % 
of cells and  MCs only the 3.48% (upper graph). 
   
5.13. Murine B cell activation  
 
Purified B cells were cultured in the presence or absence of substances known for their ability 
to induce B cell maturation and/or activation. In Annexin V/ Propidium iodide assay B cells 
were activated with recombinant human BAFF (Peprotech) (1 µg/ml) and with LPS (Sigma 
Aldrich) (10 µg/ml). In staining of BAFF-R and TACI and in experiments to evaluate AID 
expression B cells were activated with anti mouse CD40 mAb (1 µg/ml) and anti IgM mAb 
(0,5 µg/ml). 
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5.14. Annexin V/ Propidium iodide assay 
 
 
Figure 5.4 Annexin V/Propidium Iodide assay. Discrimination of viable, necrotic, late apoptotic and early 
apoptotic cells after staining with Annexin V (FITC) and Propidium Iodide (PI). 
 
This viability test allows to discriminate necrotic, apoptotic and late apoptotic cells, as shown 
in Fig. 5.4. The assay was performed using the Annexin V-FITC kit (Bender MedSystem). 
Briefly, about 300.000 cells were stained with annexin (1:40) for 10 minutes in the dark at 
room temperature. After washing with PBS cells were stained with Propidium Iodide-PI 
(1:20) and then analyzed with the citofluorimeter. Before staining with Annexin V and 
Propidium Iodide, the cells were incubated with anti-mouse CD19 Pe-Cy5 or with anti-human 
CD19 Pe-Cy5 Abs.  
 
5.15. Staining for surface markers 
 
To assess cell-surface expression of different co-stimulatory molecules and/or activation 
markers, about 0.6x106 cells were collected into polystyrene tubes (Sarstedt), washed with 
PBS, resuspended and then incubated in the dark for 30 minutes at 4°C with a fluorescent 
mAb specific for a cell surface marker or with an Ig isotype-matched control. In the case of 
multicolor staining, other fluorescent Abs directed at various cell surface Ags were added at 
the same time. After the incubation, the cells were washed with Abs, resuspended in about 0.3 
ml of PBS and kept at 4°C until flow cytometric analysis. The Abs used in the experiments 
performed for this thesis were conjugated either with fluorescein isothiocyanate (FITC), 
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phycoeritrin (PE), PE-Cy5 flurochromes or allophycocyanin (APC). A complete list of the 
Abs used in this work is shown in the table here below: 
 
 
 
Table 5.1 – List of antibodies 
Specificity of 
Antibody Reactivity Isotype Clone Conjugated Manufacturer 
Work 
diluition 
CD3 Mouse Hamster IgG 145-2C11 FITC ImmunoTools 1:100 
CD19 Mouse Rat IgG2a 1D3 FITC eBioscience 1:100 
CD19 Mouse Rat IgG2a 6D5 PE-Cy5 BioLegend 1:125 
BAFF  Mouse IgM Buffy-2 FITC abCam 1:100 
BAFF  Human Mouse IgG1,k T7-241 PE Biolegend 1:20 
BAFF Human Mouse IgG1,k 1D6 PE eBioscience 1:33 
BAFF-R Mouse Rat IgG1,k eBio7H22-E16 APC eBioscience 1:67 
TACI Mouse Rat IgG2a,k EBio8F10-3 APC eBioscience 1:67 
CD19  Human  Mouse IgG,k HIB19 Pe-Cy5 Biolegend 1:20 
CD154 (CD40L) Mouse Hamster IgG MR1 PE BioLegend 1:50 
FcεR Mouse Hamster IgG MAR-1 PE BioLegend 1:100 
CD117 (c-Kit) Mouse Rat IgG2b 2B8 PE-Cy5 eBioscience 1:100 
IL-10 Mouse Rat IgG2b,k JES5-16E3 PE Biolegend 1:50 
CD138 Human Mouse IgG1 MI15 FITC BD 1:50 
CD38 Human Mouse IgG1 HB7 APC BD 1:50 
 
Isotype controls   Clone Conjugated Manufacturer Work diluition 
Rat IgG2a    FITC BioLegend 1:100 
Rat IgG2a    PE BioLegend 1:100 
Rat IgG2b    PE eBbioscience 1:100 
Rat IgG2a    PE-Cy5 BioLegend 1:100 
Mouse IgG1,k    PE BD 1:20 
Rat IgG1    APC Biolegend 1:100 
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5.16. Preparation of protein extracts 
 
For whole protein extracts, 10x106 cells were collected, washed twice with ice-cold PBS and 
incubated for 30 minutes at 4°C, under gentle rotation, into 250 µl of RIPA BUFFER: 50 mM 
TrisHCl (pH 8), 150mM NaCl, 1 % NP40 or Triton 100x, 0.1% SDS, 0.5% NaDOC, 20 nM 
NEM. Then extracts were centrifuged at 10000 g. for 30 minutes to remove all cell debris.. 
Whole cell extracts were quantified through Bradford assay and samples were used 
immediately for western blot or stored at –80°C for future use.  
 
5.17. Western blot analysis  
 
Whole extracts were obtained as described above. Extracts were electrophoresed on a 12% 
SDS-PAGE gel. The resolved proteins were transferred to a nitrocellulose membrane 
(Schleicher & Schuell, Keene, NH). The nonspecific binding sites on the membranes were 
blocked by incubation in 5% non-fat milk in PBS/0.1% Tween-20 and then incubated with the 
indicated primary Abs for 60 minutes at room temperature. After three washes with 
PBS/0.1% Tween-20, the membranes were incubated with the appropriate anti-Ig coupled to 
peroxidase. After 60 minutes of incubation at room temperature the membranes were washed 
several times with PBS/0.1% Tween-20. Proteins were detected by ECL chemiluminescence 
(Amersham Pharmacia Biotech) using Biomax-Light films (Kodak, Rochester, NY) and 
quantitated by Gel Doc 2000 (Bio-Rad Inc.). 
Table 5.2 – List of antibodies 
Specificity of 
Antibody Reactivity Isotype Clone Conjugated Manufacturer 
Work 
diluition 
BAFF  Human  Polyclonal - abcam 1:250 
BAFF Mouse  Polyclonal - R&D  1:500 
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5.18. Intracellular staining for IL-10  
 
An intracellular staining protocol arranged by Tedder and Matsushita (Matsushita et al., 2010) 
was used to identify IL-10 producing B cells . Since the cytokine in basal conditions is not 
detectable, cells were treated with three different substances promoting its production. The 
stimulation lasted 5 h and were performed with a cocktail made by LPS (Sigma Aldrich) 
10µg/ml, Phorbol 12-Myristate 13-Acetate (PMA, SIGMA-ALDRICH) 50 ng/ml and 
ionomycin (Sigma Aldrich) 500ng/ml. Finally 2 µM monensin (Sigma Aldrich) is added to 
block the exocytosis. After the stimulation,, staining protocol is performed. Every step is 
performed at 4°C with centrifugation at 300 g for 5 minutes. Cells were collected in tubes, 
centrifuged and washed with cold PBS. After that, to identify the live cells was used 
LIVE/DEAD Fixable Green Dead Cell Stain Probe (Invitrogen) that can bind cell membrane 
of live cells and can permeate in necrotic ones is used. Sequentially the Ab CD16/32 (Fc 
block) is added for 15 minutes to avoid aspecific binding derived from the interaction with Fc 
receptors. To identify B cells 50 µl of anti-CD19 Ab diluted in PBS were added and incubated 
for 30 minutes. Cells were washed and resuspended in 250 µL of Cytofix/Cytoperm (BD 
Biosciences), a solution containing formaldehyde to fix and permeabilize cells. After 20 
minutes cells were washed twice with Perm/Wash Buffer. Then to detect the cytokine, an 
anti-IL-10 (Biolegend) Ab (or the isotype control) was added diluted in 50 µl Perm/Wash 
Buffer (BD Biosciences) and incubated for 30 minutes. Finally, the cells were washed with 
Perm/Wash Buffer and resuspended in 1.5% formaldehyde.  
 
5.19. MTT assay 
 
The MTT assay is a colorimetric assay for assessing cell viability. Yellow MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide, a tetrazole) is reduced to purple 
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formazan in the mitochondria of living cells. The absorbance of this colored solution can be 
quantified by measuring at a certain wavelength (usually between 500 and 600 nm) by a 
spectrophotometer. The absorption max is dependent on the solvent employed. This reduction 
takes place only when mitochondrial reductase enzymes are active and therefore conversion 
can be directly related to the number of viable (living) cells (Berridge et al., 2005).  
It was added 100 µl of cells (0,75x104 cells) into each well of 96-well plate and incubate cells 
for 72 h. After that it was added 20 µl of 5mg/ml MTT to each well. Include one set of wells 
with MTT but no cells (control). Cells with MTT were incubated for 3,5 h at 37 °C in 
incubator. After that it was added 150 µl of DMSO, the place was cover with tinfoil and 
agitate cells on orbital shakes for 15 minutes. The adsorbance was read at 590 nm. Each 
condition was tested in duplicate.  
 
5.20. Immunohistochemistry 
 
Four-µm thick paraffin sections were deparaffinised in HystoClear (AGTC Bioproducts, 
Hessle, UK) and rehydrated in graded alcohol series. Sections underwent microwave-oven 
heating in the Target Retrieval Solution pH 9 (Dako, Golstrup, Denmark) 1X for 15 minutes 
at 640W for Ag retrieval before endogenous peroxidase and alkaline phosphatase quenching. 
Double immunohistochemistry was performed using the EnVision G/2 Doublestain System, 
Rabbit/Mouse (DAB+/Permanent Red) kit (Dako) and the following primary Abs: 
monoclonal mouse anti-human MC tryptase (Dako), monoclonal rabbit anti-BAFF (Abcam). 
The counterstaining was performed by incubating sections with hematoxylin (Vector 
Laboratories, Burlingame, CA, USA) 1:1 in distilled water for 30 seconds. The slides were 
mounted with  the Dako Glycergel™ Mounting Medium. Sections were examined by Zeiss 
                                                                                                                               Materials and Methods 
 
 
Axioplan 2 microscope (Carl Zeiss, Jena, Germany) and images acquired by Leica 
Application Suite V4.1 software (Leica Microsystems, Wetzlar, Germany). 
 
5.21. Immunofluorescence 
 
Diagnostic Microscope Slides (10 Weel 6 mm-Thermo Scientific) were coated with 
PolyLisine (1:10 H20) at least 30 minutes. Cells (4x104 cells per well) were seeded into slides 
and fixed with 4% paraformaldehyde for 20 minutes at room temperature followed by 
permeabilization with 0.5% Triton X-100. Subsequently, reactive groups were blocked with 
FCS 10% in PBS for 30 minutes at room temperature. The cells were subjected to 
immunofluorescence staining with anti-BAFF Ab  (1:50) (Buffy-2, Abcam) for 30 minutes at 
room temperature. After labelling, slides were washed and mounted with VECTASHIELD 
Mounting Medium with DAPI (Vector Laboratories). For acquisitions, slides were mounted 
on an inverted confocal microscope (Leica AF6000 LX), equipped with a 63 x 1.40 oil 
objective.  
 
5.22. Data analysis 
 
Experimental data are represented as the mean ± standard error of mean (SEM). Statistical 
significance of the data was calculated using the τ student test. P values below 0.05 were 
considered as significant. 
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